WO2009085199A2 - Capping bioprosthetic tissue to reduce calcification - Google Patents
Capping bioprosthetic tissue to reduce calcification Download PDFInfo
- Publication number
- WO2009085199A2 WO2009085199A2 PCT/US2008/013879 US2008013879W WO2009085199A2 WO 2009085199 A2 WO2009085199 A2 WO 2009085199A2 US 2008013879 W US2008013879 W US 2008013879W WO 2009085199 A2 WO2009085199 A2 WO 2009085199A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tissue
- agent
- capping
- calcification
- solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
- A61F2/2415—Manufacturing methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0095—Packages or dispensers for prostheses or other implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
- A61F2/2418—Scaffolds therefor, e.g. support stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3625—Vascular tissue, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3629—Intestinal tissue, e.g. small intestinal submucosa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/02—Treatment of implants to prevent calcification or mineralisation in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
Definitions
- the present invention relates generally to methods for treating bioprosthetic tissue, materials, and devices to reduce post-implantation calcification, and reducing post-implantation calcification, in particular for bioprosthetic tissue used in heart valves.
- Heart valve replacement may be indicated when there is a narrowing of the native heart valve, commonly referred to as stenosis, or when the native valve leaks or regurgitates, such as when the leaflets are calcified.
- the native valve may be excised and replaced with either a biologic or a mechanical valve.
- Certain medical conditions may require grafting or suturing a tissue patch to repair physiological abnormalities. These include, but are not limited to hernia repair, vascular wounds, congenital heart defect repair and reconstruction, and bladder wall repair.
- Tissue-type or "bioprosthetic" valves have flexible tissue leaflets supported by a base structure that project into the flow stream and function much like those of a natural human heart valve by coapting against each other to ensure one-way blood flow.
- tissue-type valves a whole xenograft valve (e.g., porcine) or a plurality of xenograft leaflets (e.g., bovine or equine pericardium) typically provide fluid occluding surfaces.
- Synthetic tissue leaflets have also been proposed.
- One or more flexible leaflets mount within a peripheral support structure, for example as seen in the CARPENTIER-
- Implantable biological tissues can be formed of human tissues preserved by freezing (i.e., cryopreservation) the homograft tissues, or of animal tissues preserved by chemically fixing (i.e., tanning) the xenograft tissues.
- the type of biological tissues used as bioprostheses include cardiac valves, blood vessels, skin, dura mater, pericardium, small intestinal submucosa ("SIS tissue”), ligaments and tendons. These biological tissues typically contain connective tissue proteins (i.e., collagen and elastin) that act as the supportive framework of the tissue.
- each biological tissue is largely determined by the relative amounts of collagen and elastin present within the tissue and/or by the physical structure and configuration of its connective tissue framework.
- Collagen is the most abundant connective tissue protein present in most tissues.
- Each collagen molecule is made up of three (3) polypeptide chains intertwined in a coiled helical configuration.
- the techniques used for chemical fixation of biological tissues typically involve exposing the biological tissue to one or more chemical fixatives (i.e., tanning agents) which form cross-links between the polypeptide chains within a given collagen molecule (i.e., intramolecular cross-linkages), or between adjacent collagen molecules (i.e., intermolecular cross-linkages).
- chemical fixative agents i.e., tanning agents
- Examples of chemical fixative agents that have been used to cross-link collagenous tissues include: formaldehyde, glutaraldehyde, dialdehyde starch, hexamethylene diisocyanate and certain polyepoxy compounds.
- connective tissue proteins i.e., collagen and elastin
- calcification can result in undesirable stiffening or degradation of the bioprosthesis. This damage to the collagenous tissue leads to valve failure.
- glutaraldehyde (also referred to as simply "glut") has been the most widely used since the discovery of its anti-immunological and anti-degenerative effects by Dr. Alain Carpentier in 1968. See Carpentier, A., J. Thorac. Cardiovascular Surgery, 58: 467-69 (1969).
- glutaraldehyde is one of the most common sterilization agents.
- Glutaraldehyde is therefore used as the preferred fixative and sterilant for many commercially available bioprosthetic products, such as in the bioprosthetic heart valves available from Edwards Lifesciences of Irvine, California.
- Glutaraldehyde creates potential calcium binding sites within the tissue that can lead to calcification in vivo, such as residual aldehydes, acids, Schiff bases, etc. These groups can contribute to calcification unless mitigated via capping. Mitigating such calcification is particularly important during storage, especially when the tissue is not being stored in aqueous solution.
- U.S. 5,476,516 involve the addition of polyols (e.g., glycerol) and alcohols to bioprosthetic tissues as a calcification mitigation treatment alone, but do not address any oxidation mitigation (i.e., capping) strategies.
- U.S. 6,509,145 and U.S. 7,078,163 address oxidation of bioprosthetic tissue for the purpose of calcification mitigation.
- U.S. 6,352,708 includes glycerol preservation of fresh, "non-fixed” tissue, and treatments with glycerol and heparin, but does not include combinations of chemical treatments to prevent oxidation or reduce calcification with a glycerol drying step.
- Recently a new technique of calcium mitigation by elevated- temperature fixation of the tissue in glutaraldehyde was described in U.S. 6,561,970 (Carpentier et al.) and in combination with relative tissue/fluid movement in U.S. 5,931,969 (Carpentier et al.).
- Bioprosthetic valves are generally stored in glutaraldehyde or formaldehyde solution, and must be rinsed prior to implantation.
- Glutaraldehyde is widely used as a storage solution due to its sterilant properties but is known to contribute to calcification.
- Strategies to minimize glutaraldehyde content in the final product have been demonstrated to mitigate in vivo calcification.
- Studies have shown that storage solutions without gluaraldehyde reduce in vivo calcification compared to those with glutaraldehyde. (Mirzaie, et al. Ann Thorac Cardiovasc Surg 2007 13:102).
- One such strategy to avoid glutaraldehyde as a storage solution is to dehydrate the bioprosthetic tissue in a glycerol/ethanol mixture, sterilize with ethylene oxide, and package the final product "dry". This process circumvents the potential toxicity and calcification effects of glutaraldehyde as a sterilant and storage solution.
- glycerine, alcohols, and combinations thereof as post-glut processing methods so that the resulting tissue is in a "dry" state rather than a wet state with excess glut.
- Glycerol-based methods can be used for such storage as described in the following examples.
- the storage of heart valve tissue in glycerol was described by Parker et al. (Thorax 1978 33:638), but does not include any calcification mitigation techniques and does not describe any advantages.
- U.S. 6,534,004 (Chen et al.) describes the storage of bioprosthetic tissue in polyhydric alcohols such as glycerol.
- the tissue may be sterilized by ethylene oxide, gamma irradiation, or electron beam irradiation.
- Ethylene oxide sterilization requires exposing the tissue to increased temperatures and water vapor which will generate oxidative damage in the tissue (Olde Damink, LH. et al. J Biomed Mater Res 1995 29: 149).
- Gamma irradiation is known to generate significant reactive oxygen species in collagenous substrates which causes backbone scission and breakage of collagen fibrils (Ohan, MP et.al. J Biomed Mater Res A 2003 67:1188). This damage will lead to decreased mechanical and biochemical functionality in the tissue.
- Electron beam irradiation will also cleave the collagen backbone and lead to deterioration of the tissue structure and reactivity (Grant, RA et al. J Cell Sci 1970 7:387). Damage from oxidation during sterilization and/or storage will contribute to valve deterioration and structural failure.
- U.S. 6,605,667 discusses the addition of various antioxidant stabilizers to polymerizable adhesives, but does not address damage mitigation to bioprosthetic tissue by ionizing radiation or oxidation during storage. [0014] Although these glycerol-based methods are useful as alternatives to storage in aqueous, liquid-type solutions, they do not address the fact that the post-process functional groups (i.e.
- the present invention describes a capping method such that oxidation and other changes are dramatically reduced with storage time.
- the prior art does not address the changes within dehydrated bioprosthetic tissue during storage that occur as a result of in vitro oxidation by air or in vivo oxidation.
- the high aldehyde content in glutaraldehyde-fixed tissue is highly susceptible to oxidation, which results in calcification and tissue failure.
- the present invention teaches an improved tissue treatment method for implantable tissue devices.
- the present invention addresses certain detrimental changes within dehydrated tissue that can occur as a result of oxidation either from sterilization, atmospheric exposure during storage and handling, or from in vivo oxidation.
- the present invention involves the chemical capping of aldehydes (and other species) or otherwise neutralizing of the tissue to prevent oxidation in dehydrated tissue.
- the invention also describes the addition of chemicals (e.g. antioxidants) to the dehydration solution (ethanol/glycerol) to prevent oxidation of the tissue during sterilization (ethylene oxide, gamma irradiation, electron beam irradiation, etc.) and storage.
- the dehydration solution ethanol/glycerol
- Dehydrated bioprosthetic tissue is particularly susceptible to oxidation during sterilization and storage. The prior art does not discuss the chemical prevention of this damage for this type of bioprosthetic material.
- One object of the invention is to provide a method of mitigating calcification in bioprosthetic implant tissue, comprising: a) treating bioprosthetic implant tissue with a capping agent that reacts with functional groups on said tissue, and b) dehydrating the capped tissue with a non-aqueous solution.
- Another object is to provide calcification-resistant tissue, comprising: a) bioprosthetic implant tissue that has been treated with a capping agent which reacts with functional groups on said tissue, and b) dehydrated with a non-aqueous solution.
- Figure 1 is a graph showing the aldehyde and acid content in bovine pericardial tissue after several different chemical treatments;
- Figure 2 is a graph correlating the calcium content of in vivo tissue with the corresponding acid and aldehyde content for tissue treated three different ways;
- Figure 3 is a graph illustrating the acid and aldehyde content of various tissue treatments;
- Figure 4 is a chart showing the decrease in calcification by capping, reduction and drying (GLX process);
- Figure 5 is a chart that indicates the reduction in calcification variability by capping, reduction and drying (GLX process);
- Figure 6 is a chart showing the decrease in calcification by capping, reduction and drying (GLX process) after 80 days of real time shelf life;
- Figure 7 is a box and whisker plot of 35 Day Rabbit Intramuscular Study.
- Figure 8 is a box and whisker plot of 35 Day Rabbit Intramuscular Study, Short Term Shelf Life and Calcification Description of the Preferred Embodiments
- Bioprosthetic tissue includes, without limitation, bovine pericardium and porcine tissue which are commonly used in bioprosthetic heart valves, and blood vessels, skin, dura mater, pericardium, small intestinal submucosa (“SIS tissue”), tissue heart valves, ligaments and tendons.
- SIS tissue small intestinal submucosa
- Implants in the present application refers not only to heart valves, including transcatheter heart valves, but also to vascular prostheses and grafts, tissue grafts, bone grafts, and orbital implant wraps, among others.
- a “bioprosthetic heart valve” refers to a fully assembled prosthetic valve made at least partly from bioprosthetic tissue. Some whole porcine valves are used in so-called “stentless” bioprosthetic valves in which there is very little if any synthetic material added for support or anchoring purposes.
- a “stented” bioprosthetic valve typically has some kind of synthetic (e.g., polymer or metallic) support for the leaflets, which may be the leaflets of a whole porcine xenograft or separate bovine pericardial leaflets.
- Heart valves contemplated herein include surgical heart valves, transapical heart valves, transfemoral heart valves and other types of heart valves.
- Prior art tissue treatments address crosslinking, microbes, and other aspects of the tissue in a "static" setting, and typically involve immersion of the tissue in glutaraldehyde, Tween (polyoxyethylene 20 sorbitan monooleate), ethanol, formaldehyde, and other agents to mitigate post-implant calcification.
- Some prior art processes include the addition of various chemicals to reduce the toxicity of the crosslinked tissue or mitigate calcification via the use of metal ions (i.e., Al 3+ or Fe 3+ - see U.S. 5,746,775, Levy) or bulk blocking agents (i.e., 2-amino oleic acid - see U.S. 4.976.733, Giradot).
- Tissue treatment with glutaraldehyde, Tween (polyoxyethylene 20 sorbitan monooleate), ethanol, formaldehyde, and other agents can provide useful fixation of the tissue.
- glutaraldehyde, Tween (polyoxyethylene 20 sorbitan monooleate), ethanol, formaldehyde, and other agents can provide useful fixation of the tissue.
- it will also generate binding sites capable of interacting with or attracting calcium, phosphate, immunogenic factors, or other precursors to calcification.
- carboxylic acid groups formed after glutaraldehyde fixation of the tissue, and these groups are capable of attracting calcium ions (due to their negative charge and electrostatic interactions with positively charged ions) leading to calcification of the tissue or adverse cellular interactions.
- Carboxylic acid groups like those in glutamic acid or gamma carboxy glutamic acid are known to bind calcium atoms (Hauschka et al. PNAS 1975 72:3925).
- Calcium binding proteins such as bone sialoprotein contain carboxylic acid-rich domains designed to attract and bind calcium, leading to hydroxyapatite formation (calcification).
- the overall level and location of acid groups in these proteins determines the ability of the protein to efficiently bind calcium and form hydroxyapatite.
- the term "acid potential" of the tissue refers to the level of these chemical functional groups within the fixed tissue which may eventually form acid groups or "binding sites" by oxidation, dehydration, hydration, or similar processes.
- the inventors have discovered that such binding, causes significant post-implant damage in bioprosthetic materials, especially tissues used for heart valve leaflets.
- the oxidative damage that occurs during storage and handling of dehydrated or "dry" tissue can create carboxylic acid groups that will bind calcium and lead to tissue failure.
- This progressive leaflet damage process can create new binding sites or potential binding sites that are precursors to calcification and immunogenic related pathways.
- the present invention describes a method to cap these newly formed binding sites prior to implantation of the tissue for tissue-based bioprosthetic into the body.
- bioprosthetic tissue exposed to oxidation from the atmosphere when not submersed in a glutaraldehyde solution or during sterilization is likely to contain more acid groups that contribute to calcification and inflammation.
- the dehydrated tissue In dry storage, the dehydrated tissue is sterilized and stored "dry" without the protective effect of the glutaraldehyde solution.
- the ease of handling and storage of this new product is greatly facilitated due to the absence of the glutaraldehyde storage solution.
- This technology can be improved by treating such bioprosthetic tissue with a capping agent and/or adding a chemical protectant during the dehydration phase.
- One chemical target within the invention is the permanent "capping" of the acid groups which dramatically reduces their ability to attract calcium, phosphate, immunogenic factors, or other groups.
- the term “capping” refers to the blocking, removal, or alteration of a functional group that would have an adverse effect on the bioprosthesis properties.
- EDC l-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride
- sulfo-NHS N- hydroxysulfosuccinimide
- ethanolamine will effectively cap the acid groups with a non-reactive alcohol group.
- tissues treated with glutaraldehyde or other aldehyde-containing agents also yield tissue with many free aldehyde groups that cause increased toxicity, higher calcification, and involvement in immunogenic responses.
- These aldehyde groups can easily oxidize into carboxylic acid groups via air oxidation, in vivo blood oxidation, macrophage oxidation, and other similar oxidation pathways.
- an additional target of the invention includes the permanent capping of aldehyde groups, which are potential binding sites, in a way that would prevent or mitigate their ability to transform into acids or other groups and thus further mitigate the potential for calcification in the body (in vivo).
- the present capping process includes chemical reduction of the tissue, which, when applied to the tissue in the presence of a capping agent, will permanently connect the capping agent to the target group.
- a capping agent e.g., sodium borohydride
- the reducing agent e.g., sodium borohydride
- an aldehyde is ultimately replaced by a hydroxyl group, which may be beneficial for tissue hydration, flexibility, and cell interactions.
- capping agents can be used instead of ethanolamine and other reducing agents other than sodium borohydride and are known by those skilled in the art and which are included in the scope of this patent.
- Another preferred strategy is to oxidize the tissue aldehydes to acids, and then cap the acid groups. This may involve the addition of l-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC), N-hydroxysulfosuccinimide (sulfo-NHS), and ethanolamine.
- EDC l-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride
- sulfo-NHS N-hydroxysulfosuccinimide
- ethanolamine ethanolamine
- the invention provides a method of treating bioprosthetic implant tissue to reduce in vivo calcification of comprising at least partially cross-linking bioprosthetic implant tissue, then treating the cross-linked tissue with an aldehyde (or acid) capping solution to mitigate calcification, and dehydrating the tissue in an ethanol/glycerol solution.
- the glycerol solution may include an antioxidant treatment and may contain a water-soluble wax.
- the tissue is then allowed to dry and then subjected to final sterilization (e.g., ethylene oxide, gamma irradiation, or electron beam irradiation). The following steps describe an implementation of this process in the manufacture of prosthetic heart valves.
- Aldehyde Capping Aldehyde Capping.
- valves are briefly rinsed in 20% ethane to remove any excess glutaraldehyde adhering to the tissue. This is thought to enhance the capping process by ensuring that the capping solution can attach to aldehydes on the tissue rather than free glutaraldehyde in solution.
- the valves are then exposed to a capping solution of ethanolamine and sodium borohydride, at room temperature under agitation for 4 hours. Valves are removed from the capping solution, and rinsed for a few minutes at room temperature with the same solution used in the final bioburden reduction process to remove excess capping solution. [0038] Glycerol Treatment.
- valves After the valves have been processed through a standard final bioburden reduction step, they undergo the glycerol treatment in a solution of 75 wt% glycerol and 25 wt% ethanol. Valves are soaked in this solution for one hour at room temperature. During this time, most of the water molecules present in the pericardial tissue are replaced with glycerol. Valves are removed from the solution and placed in a clean hood to allow any excess solution to evaporate or drip off the valves.
- EO Sterilization The dehydrated valves are then ready for packaging. They are packaged in double sterile barrier packaging consisting of a rigid tray (PETG) with a Tyvek lid. The package is sealed in a cleanroom, and sterilized in 100% ethylene oxide.
- PETG rigid tray
- Tyvek lid a Tyvek lid
- the calcification mitigant preferably contains a capping agent selected from: an amine, an amino acid, an amino sulfonate, a hydrophilic multifunctional polymer, a hydrophobic multifunctional polymer, ⁇ -dicarbonyl, a hydrazides, a N,N-disuccinimidyl carbonate, a carbodiimide, 2-chloro-l-methylpyridinium iodide (CMPI), an antibiotic, a cell recruiting agent, a hemocompatibility agent, an antiinflamatory agent, an antiproliferative agent, an immunogenic suppressing agent, a reducing agent, and a mono-, di- or polyepoxy alkane.
- a capping agent selected from: an amine, an amino acid, an amino sulfonate, a hydrophilic multifunctional polymer, a hydrophobic multifunctional polymer, ⁇ -dicarbonyl, a hydrazides, a N,N-disuccin
- the chemical anti-oxidant is desirably selected from : a water soluble antioxidant such as ascorbic acid, a fat soluble antioxidant such as tocopherols, a carbohydrate such as fructose, sucrose, or mannitol a hindered phenol such as butylated hydroxytoluene (BHT), a hindered amine light stabilizer (HALS) such as p-phenylamine diamine, trimethyl dihydrodquinoline, or alkylated diphenyl amines a phosphite/phosphonite such as triphenyl phosphine, and a thioester such as a thiocinnamate
- a water soluble antioxidant such as ascorbic acid
- a fat soluble antioxidant such as tocopherols
- carbohydrate such as fructose, sucrose, or mannitol
- a hindered phenol such as butylated hydroxytoluene (BHT)
- the calcification mitigant (capping agent) and/or the chemical oxidation protectant is desirably delivered in one or a combination of the following selected solutions: an aqueous solution such as an aqueous buffered solution, water, short chain alcohols, glycerol, or plasticizers, an organic solvent, and an organic buffered solution.
- an aqueous solution such as an aqueous buffered solution, water, short chain alcohols, glycerol, or plasticizers
- an organic solvent such as an aqueous buffered solution
- an organic solvent such as an organic solvent
- organic buffered solution an organic buffered solution.
- the tissue is preferably fully cross-linked prior to the capping process.
- th ⁇ > tissue comprises precut heart valve leaflets mounted and treated in a suitable apparatus.
- the tissue may be bulk sheets of tissue treated in a suitable apparatus.
- capping agents examples are: amines, alkyl amines, amino alcohols, ethanolamine, amino acids, lysine, hydroxylysine, amino sulfonates, taurine, amino sulfates, dextran sulfate, chondroitin sulfate, hydrophilic multifunctional polymer, polyvinyl alcohol, polyethyleneimine, hydrophobic multifunctional polymer, ⁇ -dicarbonyls methylglyoxal 3 -deoxyglucosone glyoxal hydrazides adipic hydrazide N,N-disuccinimidyl carbonate carbodiimides l-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC)
- DCC 1,3-dicyclohexyl carbodiimide
- CMPI 2-chloro-l-methylpyridinium iodide
- DCC 2-chloro-l-methylpyridinium iodide
- CMPI 2-chloro-l-methylpyridinium iodide
- an antibiotic a cell recruiting agent, a hemocompatibility agent, heparin, an anti-inflammatory agent, an antiproliferative agent, an immunogenic suppressing agent, a reducing agent, sodium cyanoborohydride, sodium borohydride, sodium bisulfite + acetylacetone, formic acid + formaldehyde, and mono-, di- or polyepoxy alkanes.
- the effect of preferred capping agents is to not only block functional groups that will attract calcium, phosphate, immunogenic factors, or other similar agents, but to replace those groups with a superior biological functionality.
- biological functionality is defined as the effect of tissue components on the local biology of the implanted material. Improved biological functionality of a tissue treatment may include reduction in overall charge of the tissue, better hemocompatibility, increased tissue hydration, better cell interactions, better flexibility, etc.
- capping aldehyde functions with ethanolamine blocks the aldehyde group from oxidizing into an acid and replaces it with a hydroxyl group, which may be beneficial for tissue hydration, flexibility, and cell interactions.
- the desired biological functionality of the capped tissue will determine the type of capping compounds employed.
- the capping strategy is also designed to block the biological functionality of components of the tissue that may contribute to adverse cellular reactions.
- Some of these targets include, but are not limited to ⁇ -gal, MHC-I associated proteins, HLA antigens and the like.
- the invention addresses the capping or blocking of proteins, carbohydrates, lipids, and other components of the tissue that may contribute to cellular reactions.
- the ⁇ -gal carbohydrate may be blocked by treatment with 2-chloro-l-methylpyridinium iodide (CMPI) and other agents that neutralize the hydroxyl groups which are known by those skilled in the art.
- CMPI 2-chloro-l-methylpyridinium iodide
- MHC-I associated proteins that may be capped or effectively neutralized by treatment with 1- ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) and ethanolamine.
- EDC 1- ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride
- ethanolamine also included in the invention's capping process is the targeting of proteins, carbohydrates or lipids associated with cell and vessel remnants.
- fibronectin may be capped or blocked by the addition of methylglyoxal to the tissue. This dicarbonyl is known to bind critical arginine functions within proteins and impairs the biological functionality of these proteins.
- Another aspect of the invention includes the activation of capping technology upon sterilization.
- tissue e.g. glucose and ethanolamine or taurine
- specific capping agents e.g. glucose and ethanolamine or taurine
- the capping agents added to the tissue would effectively cap targets within the tissue immediately, but sterilization (i.e. ethylene oxide, electron beam irradiation, or gamma irradiation) would generate new binding sites that would then be capped by the residual capping agents within the tissue.
- sterilization i.e. ethylene oxide, electron beam irradiation, or gamma irradiation
- Gamma irradiation of collagen is known to cleave peptide bonds within the backbone and produce new functional groups that may have adverse effects on the tissue. These new functional groups are included in the targets or binding sites described herein and may be capped or blocked by the capping agents listed herein.
- Immunogenic factors are defined as anything causing or involved in stimulating an immunogenic response. These include any chemical or biological agent capable of inducing an immune type response. For example, vessel and cell membrane components left in the tissue may cause some type of immunogenic or antigenic response from the body's natural immune system.
- the invention includes capping agents capable of masking, replacing, or blocking these immunogenic elements in the tissue either statically or dynamically. For example, a whole valve could be fixed, then capped with a non-immunogenic or more hemocompatible capping agent such as heparin prior to dehydration and sterilization. This is different from prior art processes that add heparin to fixed tissue without any dehydration of the valve or any consideration of the post-process oxidation conditions.
- the invention process can be supplemented with a decellularization process to reduce immunologic or antigenic binding sites and potential binding sites and is also within the scope of this invention.
- the invention generally comprises treating tissue so that calcium or phosphate binding sites, or other such sites which could trigger calcification, are capped.
- the correlation between acid binding sites and tissue calcification can be seen in ( Figure 2 see also Hauschka et al. PNAS 1975 72:3925.) and it appears that acid templating directs mineralization in a variety of species.
- the amount of free acids and/or aldehydes in the tissue at the time of implantation correlates with the number of such binding sites and, therefore, increases the potential for calcification.
- Figure 1 is a graph showing both the free aldehyde and free acid content in bovine pericardial tissue as measured by the aforementioned technique. It should be understood that all of the tests referred to herein involve glutaraldehyde-fixed bovine pericardial tissue. The tissues studied have all been chemically treated, one with glutaraldehyde only, and two others with tissue treatments that have been used by Edwards Lifesciences to prepare commercial bioprosthetic tissue for implant. However, other cross-linking and tissue processing methods can be used and are within the scope of this invention.
- the aldehyde and acid content of the tissues is measured subsequent to the chemical treatments, and without any damage or stress imparted to the tissue.
- the tissue samples On the right side of the graph of Figure 1, the tissue samples have been treated in glutaraldehyde only, in particular in a solution of 0.625% glutaraldehyde for a period of 14 days. A total of 10 samples were treated and subsequently tested. The measurements showed an average level of about 40 nanomoles of aldehydes and about 17 nanomoles of acids per milligram of dry weight of the tissue.
- the middle of the graph of Figure 1 shows the results from testing a total of 10 tissue samples subjected to Treatment A, which is commercially known as the XenoLogiXTM tissue treatment process from Edwards Lifesciences of Irvine, CA.
- Treatment A involves first fixing with glutaraldehyde then treating twice with a sterilant including a cross-linking agent such as formaldehyde, a surfactant such as Tween-80 (Polyoxyethylene sorbitan monooleate), and a denaturant such as ethyl alcohol.
- Treatment B which is commercially known as the Carpentier-Edwards ThermaFixTM tissue treatment process from Edwards Lifesciences.
- Treatment B is essentially the same as Treatment A, with the addition of a heat treating step after fixing and prior to sterilizing. Both the aldehyde and acid content of the tissue subjected to Treatment B were less than that of tissue treated glutaraldehyde alone, with the aldehyde content decreasing by about 33% and the acid content by more than 50%. In addition, Treatment B reduces both the aldehyde and acid content relative to Treatment A by between 10-20%.
- Figure 2 is a graph that repeats the results of aldehyde/acid content measurements for the three tissue treatments shown in Figure 1, and also superimposes measurements of calcium uptake from like tissue samples implanted subcutaneously in rabbits from a separate study. These acid levels are measured in the tissue prior to implant and are likely to increase in vivo.
- Figure 2 reveals that the amount of calcium found in the implanted tissues correlates with the levels of aldehydes/acids from the three tissue treatments. That is, as the level of free aldehydes and free acids in the various tissue samples decreases, the amount of calcium absorbed upon implant also decreases.
- FIGS. 4 and 5 are the results of a rabbit intramuscular implant study indicating that the GLX process (described in this invention) significantly reduces calcification over current technology (TFX) and over simple glycerol treatment (GLY-treated). These data also indicate that the GLX process reduces variability in calcification. All calcification measurements were measured by atomic absorption spectroscopy and normalized to dry weight of lyophilized tissue.
- Figures 6 and 7 illustrate that after 80 days of real time shelf life, the GLX treated tissue shows significantly less calcification than TFX or the glycerol treatment alone. The GLX process also reduces variability after 80 days of shelf life. All calcification measurements were measured by atomic absorption spectroscopy and normalized to dry weight of lyophilized tissue.
- the inventors believe that the oxidative damage of dehydrated tissue imparted on bioprosthetic tissue greatly contributes to the propensity for calcification of tissue.
- heart valve leaflets not stored in glutaraldehyde are subjected to significant oxidative damage.
- This deleterious tissue damage process can create new binding sites not previously detected or recognized, as potential attachment sites of calcium and phosphate ions, thereby initiating calcification.
- the present invention involves mitigating oxidation by capping the numerous aldehydes that are susceptible to oxidation and increased calcification initiation.
- the preferred embodiments include, but are not limited to:
- the fixed tissue valve or tissue sheet is treated in a solution containing an aldehyde capping agent.
- Embodiment 1 but where a sterilization step is added during or after the capping process.
- Embodiments 1 and 2 but where the processing is agitated.
- the aldehyde capping solution may contain an amine (10 itiM ethanolamine) and a reducing agent (132 mM sodium borohydride) in 50 mM phosphate buffer at pH 7.4.
- tissue or valve is then dehydrated in a glycerol solution 7.
- tissue or valve is then sterilized with ethylene oxide
- Example 1 Aldehyde capping using ethanolamine and sodium borohydride of glutaraldehyde-fixed tissue.
- Bioprosthetic tissue was removed from 0.625% glutaraldehyde just after heat treatment step and rinsed in ethanol: saline (20% / 80%) for 2 minutes.
- One liter of capping solution was prepared containing 1OmM ethanolamine (0.06%), and HOmM sodium borohydride (0.42%) in 5OmM phosphate buffer (pH 7.3 - 7.8)
- the capping solution was placed on an orbital shaker, then tissues (leaflets or valves) were placed in the solution so that they were completely submerged.
- the ratio of tissue to solution was 3 leaflets per 100ml or one valve per 100 ml.
- the container was partly covered but not completely sealed because hydrogen gas liberated by the chemical reaction with water could cause the container to explode.
- the orbital shaker was operated at between 80-100 rpm for 4 hours at room temperature.
- the tissue was removed and rinsed in FET solution (formaldehyde, ethanol, tween-80) for three minutes.
- Example 2 - Glycerol dehydration process for pericardial valve bioprosthesis Pericardial valves were dehydrated by holding each valve with forceps on the sewing ring of the valve and placing the valve in a glycerol/ethanol (75%/25%) mixture. Beakers containing the valves were placed on an orbital shaker operating between 50-60 RPM for at least one (1) hour but not more than four (4) hours then immediately treated to remove excess glycerol. This was done by holding them with forceps on the sewing ring of the valve, taking the valve out of the glycerol/ethanol mixture and then placing it on an absorbent towel in a wide mouth jar. After being allowed to dry for at least 5 minutes at room temperature the jar was attached to a lyophilizer and dried for 2 hours. Valves were then transferred to ethylene oxide gas permeable packages and sterilized with ethylene oxide.
- Example 3 Calcification Mitigation - Small Animal Model.
- calcification mitigation properties of GLX treated and EO sterilized pericardial tissue two small animal feasibility studies were conducted.
- Example 3 A - Rabbit Study #1. Calcification Potential of Ethylene Oxide Sterilization on GLX Processed Pericardial Tissue in a 35 Day Rabbit Intramuscular Study.
- a study utilizing sixty (60) rabbits was conducted to look at the effects on calcification of GLX treated pericardium sterilized using 100% ethylene oxide.
- the control group was ThermaFix (TFX) processed bovine pericardium and the test group was GLX processed pericardium.
- TFX ThermaFix
- GLX data also showed reduced outliers and reduced variability. Box and Whisker plots show an appreciable reduction in variability with the GLX process. Data are presented in Figure 7, with the y-axis measuring ⁇ g calcium / mg dry weight tissue.
- Example 3B - Rabbit Study #2 Effects of a Short Term Shelf Life on Calcification of GLX Processed Pericardial Tissue in a 35 Day Rabbit Intramuscular Study.
- a second study utilizing sixty (60) additional rabbits was conducted to look at the effects on calcification of short term shelf life of GLX processed pericardium.
- the control group was ThermaFix (TFX) processed bovine pericardium and the test group was GLX processed pericardium.
- the GLX tissue samples were packaged in Tyvek pouches and sterilized via 100% ethylene oxide.
- GLX samples were stored in a controlled steady state chamber at 25 oC and 60% humidity for a period of 83 days. The TFX samples had not been aged.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2710366A CA2710366C (en) | 2007-12-21 | 2008-12-19 | Capping bioprosthetic tissue to reduce calcification |
EP18197247.2A EP3453409B1 (en) | 2007-12-21 | 2008-12-19 | Capping bioprosthetic tissue to reduce calcification |
CN200880126930.4A CN101965205B (en) | 2007-12-21 | 2008-12-19 | Capping bioprosthetic tissue to reduce calcification |
EP13003386.3A EP2647393B1 (en) | 2007-12-21 | 2008-12-19 | Capping bioprosthetic tissue to reduce calcification |
EP08866741.5A EP2234657B1 (en) | 2007-12-21 | 2008-12-19 | Capping bioprosthetic tissue to reduce calcification |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1626307P | 2007-12-21 | 2007-12-21 | |
US61/016,263 | 2007-12-21 | ||
US12/338,872 US8357387B2 (en) | 2007-12-21 | 2008-12-18 | Capping bioprosthetic tissue to reduce calcification |
US12/338,872 | 2008-12-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009085199A2 true WO2009085199A2 (en) | 2009-07-09 |
WO2009085199A3 WO2009085199A3 (en) | 2009-12-17 |
Family
ID=40789552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/013879 WO2009085199A2 (en) | 2007-12-21 | 2008-12-19 | Capping bioprosthetic tissue to reduce calcification |
Country Status (5)
Country | Link |
---|---|
US (7) | US8357387B2 (en) |
EP (3) | EP2647393B1 (en) |
CN (2) | CN103705980B (en) |
CA (1) | CA2710366C (en) |
WO (1) | WO2009085199A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021119391A1 (en) * | 2019-12-12 | 2021-06-17 | Edwards Lifesciences Corporation | Hybrid annuloplasty ring |
Families Citing this family (191)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0850607A1 (en) | 1996-12-31 | 1998-07-01 | Cordis Corporation | Valve prosthesis for implantation in body channels |
US6454799B1 (en) | 2000-04-06 | 2002-09-24 | Edwards Lifesciences Corporation | Minimally-invasive heart valves and methods of use |
US7556646B2 (en) | 2001-09-13 | 2009-07-07 | Edwards Lifesciences Corporation | Methods and apparatuses for deploying minimally-invasive heart valves |
US6733525B2 (en) | 2001-03-23 | 2004-05-11 | Edwards Lifesciences Corporation | Rolled minimally-invasive heart valves and methods of use |
US6893460B2 (en) | 2001-10-11 | 2005-05-17 | Percutaneous Valve Technologies Inc. | Implantable prosthetic valve |
US8308797B2 (en) | 2002-01-04 | 2012-11-13 | Colibri Heart Valve, LLC | Percutaneously implantable replacement heart valve device and method of making same |
DE102005003632A1 (en) | 2005-01-20 | 2006-08-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Catheter for the transvascular implantation of heart valve prostheses |
US7780723B2 (en) | 2005-06-13 | 2010-08-24 | Edwards Lifesciences Corporation | Heart valve delivery system |
WO2007058857A2 (en) | 2005-11-10 | 2007-05-24 | Arshad Quadri | Balloon-expandable, self-expanding, vascular prosthesis connecting stent |
EP2077718B2 (en) * | 2006-10-27 | 2022-03-09 | Edwards Lifesciences Corporation | Biological tissue for surgical implantation |
US8236045B2 (en) | 2006-12-22 | 2012-08-07 | Edwards Lifesciences Corporation | Implantable prosthetic valve assembly and method of making the same |
US8105375B2 (en) * | 2007-01-19 | 2012-01-31 | The Cleveland Clinic Foundation | Method for implanting a cardiovascular valve |
US7896915B2 (en) | 2007-04-13 | 2011-03-01 | Jenavalve Technology, Inc. | Medical device for treating a heart valve insufficiency |
US9101691B2 (en) | 2007-06-11 | 2015-08-11 | Edwards Lifesciences Corporation | Methods for pre-stressing and capping bioprosthetic tissue |
DE102007043830A1 (en) | 2007-09-13 | 2009-04-02 | Lozonschi, Lucian, Madison | Heart valve stent |
US8357387B2 (en) * | 2007-12-21 | 2013-01-22 | Edwards Lifesciences Corporation | Capping bioprosthetic tissue to reduce calcification |
US9044318B2 (en) | 2008-02-26 | 2015-06-02 | Jenavalve Technology Gmbh | Stent for the positioning and anchoring of a valvular prosthesis |
ES2903231T3 (en) | 2008-02-26 | 2022-03-31 | Jenavalve Tech Inc | Stent for positioning and anchoring a valve prosthesis at an implantation site in a patient's heart |
EP2265225B1 (en) | 2008-02-29 | 2013-02-13 | Edwards Lifesciences Corporation | Expandable member for deploying a prosthetic device |
US20090276040A1 (en) | 2008-05-01 | 2009-11-05 | Edwards Lifesciences Corporation | Device and method for replacing mitral valve |
US8323335B2 (en) | 2008-06-20 | 2012-12-04 | Edwards Lifesciences Corporation | Retaining mechanisms for prosthetic valves and methods for using |
US8652202B2 (en) | 2008-08-22 | 2014-02-18 | Edwards Lifesciences Corporation | Prosthetic heart valve and delivery apparatus |
CN102292053A (en) | 2008-09-29 | 2011-12-21 | 卡迪尔克阀门技术公司 | Heart valve |
WO2010040009A1 (en) | 2008-10-01 | 2010-04-08 | Cardiaq Valve Technologies, Inc. | Delivery system for vascular implant |
US8690936B2 (en) | 2008-10-10 | 2014-04-08 | Edwards Lifesciences Corporation | Expandable sheath for introducing an endovascular delivery device into a body |
CA2961053C (en) | 2009-04-15 | 2019-04-30 | Edwards Lifesciences Cardiaq Llc | Vascular implant and delivery system |
US9730790B2 (en) | 2009-09-29 | 2017-08-15 | Edwards Lifesciences Cardiaq Llc | Replacement valve and method |
CN101721745B (en) * | 2009-11-09 | 2015-04-01 | 山东省千佛山医院 | Method for processing donkey pericardium for artificial heart valve and other biological repairing material |
US8449599B2 (en) | 2009-12-04 | 2013-05-28 | Edwards Lifesciences Corporation | Prosthetic valve for replacing mitral valve |
JP2013512765A (en) | 2009-12-08 | 2013-04-18 | アヴァロン メディカル リミテッド | Devices and systems for transcatheter mitral valve replacement |
US8869982B2 (en) | 2009-12-18 | 2014-10-28 | Edwards Lifesciences Corporation | Prosthetic heart valve packaging and deployment system |
US8839957B2 (en) * | 2010-02-15 | 2014-09-23 | Michael C. Murad | Prosthetic heart valve packaging system |
SG10201501500TA (en) * | 2010-03-01 | 2015-04-29 | Colibri Heart Valve Llc | Percutaneously deliverable heart valve and methods associated therewith |
AU2013204420B2 (en) * | 2010-03-01 | 2014-07-31 | Colibri Heart Valve Llc | Percutaneously deliverable heart valve and methods associated therewith |
US8679404B2 (en) | 2010-03-05 | 2014-03-25 | Edwards Lifesciences Corporation | Dry prosthetic heart valve packaging system |
NZ602706A (en) | 2010-03-23 | 2014-02-28 | Edwards Lifesciences Corp | Methods of conditioning sheet bioprosthetic tissue |
US8579964B2 (en) | 2010-05-05 | 2013-11-12 | Neovasc Inc. | Transcatheter mitral valve prosthesis |
BR112012029896A2 (en) | 2010-05-25 | 2017-06-20 | Jenavalve Tech Inc | prosthetic heart valve for stent graft and stent graft |
IT1400545B1 (en) | 2010-06-09 | 2013-06-11 | Sorin Biomedica Cardio Srl | PROCEDURE FOR THE PREPARATION OF BIOLOGICAL FABRIC FOR BIOLOGICAL PROSTHESIS. |
IT1400544B1 (en) * | 2010-06-09 | 2013-06-11 | Sorin Biomedica Cardio Srl | PROCESS OF DETOXIFICATION OF BIOLOGICAL FABRIC. |
US8906601B2 (en) | 2010-06-17 | 2014-12-09 | Edwardss Lifesciences Corporation | Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates |
CA2794135C (en) * | 2010-06-17 | 2018-01-02 | Edwards Lifesciences Corporation | Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates |
CA2806544C (en) | 2010-06-28 | 2016-08-23 | Colibri Heart Valve Llc | Method and apparatus for the endoluminal delivery of intravascular devices |
WO2012027515A2 (en) | 2010-08-24 | 2012-03-01 | Southern Lights Ventures 2002 Limited | Biomaterials with enhanced properties and devices made therefrom |
EP3459500B1 (en) | 2010-09-23 | 2020-09-16 | Edwards Lifesciences CardiAQ LLC | Replacement heart valves and delivery devices |
US9351829B2 (en) * | 2010-11-17 | 2016-05-31 | Edwards Lifesciences Corporation | Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability |
JP2014507179A (en) | 2010-12-14 | 2014-03-27 | コリブリ ハート バルブ エルエルシー | Percutaneously deliverable heart valve including folded membrane cusps with integrated leaflets |
US9498317B2 (en) | 2010-12-16 | 2016-11-22 | Edwards Lifesciences Corporation | Prosthetic heart valve delivery systems and packaging |
CN102114270B (en) * | 2011-02-22 | 2013-08-07 | 上海微创医疗器械(集团)有限公司 | Gradient cross linking and modifying type durable prosthetic biological valve and preparation method thereof |
US9155619B2 (en) | 2011-02-25 | 2015-10-13 | Edwards Lifesciences Corporation | Prosthetic heart valve delivery apparatus |
US9308087B2 (en) | 2011-04-28 | 2016-04-12 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US9554897B2 (en) | 2011-04-28 | 2017-01-31 | Neovasc Tiara Inc. | Methods and apparatus for engaging a valve prosthesis with tissue |
US8968394B2 (en) | 2011-05-12 | 2015-03-03 | Edwards Lifesciences Corporation | Mitral heart valve holder and storage system |
US9289282B2 (en) | 2011-05-31 | 2016-03-22 | Edwards Lifesciences Corporation | System and method for treating valve insufficiency or vessel dilatation |
KR101246721B1 (en) | 2011-06-13 | 2013-03-26 | 한국원자력연구원 | A combined irradiation method with polyglutamic acid for preventing the decrease in the physical and physiological properties of skin or tendon tissues and skin or tendon substitutes by sterilization |
AU2012282660B2 (en) * | 2011-07-11 | 2017-07-27 | The Children's Hospital Of Philadelphia | Oxidation resistant bioprosthetic tissues and preparation thereof |
US9119716B2 (en) | 2011-07-27 | 2015-09-01 | Edwards Lifesciences Corporation | Delivery systems for prosthetic heart valve |
AU2012299311B2 (en) | 2011-08-11 | 2016-03-03 | Tendyne Holdings, Inc. | Improvements for prosthetic valves and related inventions |
FR2979534B1 (en) * | 2011-09-06 | 2013-12-27 | Protip | NEW INTRALARYNGEE PROSTHESIS |
FR2983060B1 (en) | 2011-11-30 | 2013-12-06 | Protip | MEDICAL SUPPORT DEVICE FOR IMPLANT OR PROSTHESIS |
CA3201836A1 (en) | 2011-12-09 | 2013-06-13 | Edwards Lifesciences Corporation | Prosthetic heart valve having improved commissure supports |
US9827092B2 (en) | 2011-12-16 | 2017-11-28 | Tendyne Holdings, Inc. | Tethers for prosthetic mitral valve |
EP2832376B1 (en) | 2012-03-31 | 2017-09-06 | Waseda University | Method for treating biological tissue and biological tissue |
US9345573B2 (en) | 2012-05-30 | 2016-05-24 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
US9301835B2 (en) | 2012-06-04 | 2016-04-05 | Edwards Lifesciences Corporation | Pre-assembled bioprosthetic valve and sealed conduit |
WO2014022124A1 (en) | 2012-07-28 | 2014-02-06 | Tendyne Holdings, Inc. | Improved multi-component designs for heart valve retrieval device, sealing structures and stent assembly |
US9675454B2 (en) | 2012-07-30 | 2017-06-13 | Tendyne Holdings, Inc. | Delivery systems and methods for transcatheter prosthetic valves |
US9693862B2 (en) | 2012-07-31 | 2017-07-04 | Edwards Lifesciences Corporation | Holders for prosthetic heart valves |
US20140067048A1 (en) | 2012-09-06 | 2014-03-06 | Edwards Lifesciences Corporation | Heart Valve Sealing Devices |
US9585748B2 (en) | 2012-09-25 | 2017-03-07 | Edwards Lifesciences Corporation | Methods for replacing a native heart valve and aorta with a prosthetic heart valve and conduit |
US10058630B2 (en) * | 2012-10-22 | 2018-08-28 | Concievalve, Llc | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
US9844436B2 (en) | 2012-10-26 | 2017-12-19 | Edwards Lifesciences Corporation | Aortic valve and conduit graft implant tool |
US10238771B2 (en) | 2012-11-08 | 2019-03-26 | Edwards Lifesciences Corporation | Methods for treating bioprosthetic tissue using a nucleophile/electrophile in a catalytic system |
US9439763B2 (en) | 2013-02-04 | 2016-09-13 | Edwards Lifesciences Corporation | Prosthetic valve for replacing mitral valve |
US9168129B2 (en) | 2013-02-12 | 2015-10-27 | Edwards Lifesciences Corporation | Artificial heart valve with scalloped frame design |
US10583002B2 (en) | 2013-03-11 | 2020-03-10 | Neovasc Tiara Inc. | Prosthetic valve with anti-pivoting mechanism |
US9730791B2 (en) | 2013-03-14 | 2017-08-15 | Edwards Lifesciences Cardiaq Llc | Prosthesis for atraumatically grasping intralumenal tissue and methods of delivery |
US9681951B2 (en) | 2013-03-14 | 2017-06-20 | Edwards Lifesciences Cardiaq Llc | Prosthesis with outer skirt and anchors |
CA2900367C (en) | 2013-03-15 | 2020-12-22 | Edwards Lifesciences Corporation | Valved aortic conduits |
US9486306B2 (en) | 2013-04-02 | 2016-11-08 | Tendyne Holdings, Inc. | Inflatable annular sealing device for prosthetic mitral valve |
US10463489B2 (en) | 2013-04-02 | 2019-11-05 | Tendyne Holdings, Inc. | Prosthetic heart valve and systems and methods for delivering the same |
US11224510B2 (en) | 2013-04-02 | 2022-01-18 | Tendyne Holdings, Inc. | Prosthetic heart valve and systems and methods for delivering the same |
US9572665B2 (en) | 2013-04-04 | 2017-02-21 | Neovasc Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
US10478293B2 (en) | 2013-04-04 | 2019-11-19 | Tendyne Holdings, Inc. | Retrieval and repositioning system for prosthetic heart valve |
ES2908132T3 (en) | 2013-05-20 | 2022-04-27 | Edwards Lifesciences Corp | Prosthetic Heart Valve Delivery Apparatus |
US9610159B2 (en) | 2013-05-30 | 2017-04-04 | Tendyne Holdings, Inc. | Structural members for prosthetic mitral valves |
JP6461122B2 (en) | 2013-06-25 | 2019-01-30 | テンダイン ホールディングス,インコーポレイテッド | Thrombus management and structural compliance features of prosthetic heart valves |
CA2919379C (en) | 2013-08-01 | 2021-03-30 | Tendyne Holdings, Inc. | Epicardial anchor devices and methods |
WO2015028209A1 (en) | 2013-08-30 | 2015-03-05 | Jenavalve Technology Gmbh | Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame |
FR3009951B1 (en) | 2013-09-05 | 2017-01-20 | Protip | INTRA-LARYNGEAL PROSTHESIS |
US9615922B2 (en) | 2013-09-30 | 2017-04-11 | Edwards Lifesciences Corporation | Method and apparatus for preparing a contoured biological tissue |
US10959839B2 (en) | 2013-10-08 | 2021-03-30 | Edwards Lifesciences Corporation | Method for directing cellular migration patterns on a biological tissue |
WO2015058039A1 (en) | 2013-10-17 | 2015-04-23 | Robert Vidlund | Apparatus and methods for alignment and deployment of intracardiac devices |
CN108403261B (en) | 2013-10-28 | 2021-02-12 | 坦迪尼控股股份有限公司 | Prosthetic heart valves and systems and methods for delivering prosthetic heart valves |
US9526611B2 (en) | 2013-10-29 | 2016-12-27 | Tendyne Holdings, Inc. | Apparatus and methods for delivery of transcatheter prosthetic valves |
US20150122687A1 (en) * | 2013-11-06 | 2015-05-07 | Edwards Lifesciences Corporation | Bioprosthetic heart valves having adaptive seals to minimize paravalvular leakage |
US9622863B2 (en) | 2013-11-22 | 2017-04-18 | Edwards Lifesciences Corporation | Aortic insufficiency repair device and method |
US10098734B2 (en) | 2013-12-05 | 2018-10-16 | Edwards Lifesciences Corporation | Prosthetic heart valve and delivery apparatus |
WO2016126942A2 (en) | 2015-02-05 | 2016-08-11 | Vidlund Robert M | Expandable epicardial pads and devices and methods for delivery of same |
WO2015120122A2 (en) | 2014-02-05 | 2015-08-13 | Robert Vidlund | Apparatus and methods for transfemoral delivery of prosthetic mitral valve |
US9986993B2 (en) | 2014-02-11 | 2018-06-05 | Tendyne Holdings, Inc. | Adjustable tether and epicardial pad system for prosthetic heart valve |
USD755384S1 (en) | 2014-03-05 | 2016-05-03 | Edwards Lifesciences Cardiaq Llc | Stent |
EP3116409B1 (en) | 2014-03-10 | 2023-07-26 | Tendyne Holdings, Inc. | Devices for positioning and monitoring tether load for prosthetic mitral valve |
US10195025B2 (en) | 2014-05-12 | 2019-02-05 | Edwards Lifesciences Corporation | Prosthetic heart valve |
US9532870B2 (en) | 2014-06-06 | 2017-01-03 | Edwards Lifesciences Corporation | Prosthetic valve for replacing a mitral valve |
US10195026B2 (en) | 2014-07-22 | 2019-02-05 | Edwards Lifesciences Corporation | Mitral valve anchoring |
US10058424B2 (en) | 2014-08-21 | 2018-08-28 | Edwards Lifesciences Corporation | Dual-flange prosthetic valve frame |
EP3242630A2 (en) | 2015-01-07 | 2017-11-15 | Tendyne Holdings, Inc. | Prosthetic mitral valves and apparatus and methods for delivery of same |
US10119882B2 (en) | 2015-03-10 | 2018-11-06 | Edwards Lifesciences Corporation | Surgical conduit leak testing |
US10010417B2 (en) | 2015-04-16 | 2018-07-03 | Edwards Lifesciences Corporation | Low-profile prosthetic heart valve for replacing a mitral valve |
US10064718B2 (en) | 2015-04-16 | 2018-09-04 | Edwards Lifesciences Corporation | Low-profile prosthetic heart valve for replacing a mitral valve |
CA2983002C (en) | 2015-04-16 | 2023-07-04 | Tendyne Holdings, Inc. | Apparatus and methods for delivery, repositioning, and retrieval of transcatheter prosthetic valves |
US10709555B2 (en) | 2015-05-01 | 2020-07-14 | Jenavalve Technology, Inc. | Device and method with reduced pacemaker rate in heart valve replacement |
CN106190949B (en) | 2015-05-08 | 2020-04-10 | 上海微创心通医疗科技有限公司 | Dry animal-derived collagen fiber tissue material, preparation method thereof and bioprosthesis |
CN108535205B (en) * | 2015-07-22 | 2021-06-22 | 杭州启明医疗器械股份有限公司 | In-vitro biological valve anti-calcification treatment method and calcification evaluation method |
US10350047B2 (en) | 2015-09-02 | 2019-07-16 | Edwards Lifesciences Corporation | Method and system for packaging and preparing a prosthetic heart valve and associated delivery system |
US10327894B2 (en) | 2015-09-18 | 2019-06-25 | Tendyne Holdings, Inc. | Methods for delivery of prosthetic mitral valves |
US10470876B2 (en) | 2015-11-10 | 2019-11-12 | Edwards Lifesciences Corporation | Transcatheter heart valve for replacing natural mitral valve |
US10376364B2 (en) | 2015-11-10 | 2019-08-13 | Edwards Lifesciences Corporation | Implant delivery capsule |
ES2777609T3 (en) | 2015-12-03 | 2020-08-05 | Tendyne Holdings Inc | Framework Features for Prosthetic Mitral Valves |
US10357351B2 (en) | 2015-12-04 | 2019-07-23 | Edwards Lifesciences Corporation | Storage assembly for prosthetic valve |
WO2017117109A1 (en) | 2015-12-28 | 2017-07-06 | Tendyne Holdings, Inc. | Atrial pocket closures for prosthetic heart valves |
CN108882981B (en) | 2016-01-29 | 2021-08-10 | 内奥瓦斯克迪亚拉公司 | Prosthetic valve for preventing outflow obstruction |
US10470877B2 (en) | 2016-05-03 | 2019-11-12 | Tendyne Holdings, Inc. | Apparatus and methods for anterior valve leaflet management |
CN109475419B (en) | 2016-05-13 | 2021-11-09 | 耶拿阀门科技股份有限公司 | Heart valve prosthesis delivery systems and methods for delivering heart valve prostheses through guide sheaths and loading systems |
US11039921B2 (en) | 2016-06-13 | 2021-06-22 | Tendyne Holdings, Inc. | Sequential delivery of two-part prosthetic mitral valve |
CN109640887B (en) | 2016-06-30 | 2021-03-16 | 坦迪尼控股股份有限公司 | Prosthetic heart valve and apparatus and method for delivering same |
WO2018013515A1 (en) | 2016-07-12 | 2018-01-18 | Tendyne Holdings, Inc. | Apparatus and methods for trans-septal retrieval of prosthetic heart valves |
US10350062B2 (en) | 2016-07-21 | 2019-07-16 | Edwards Lifesciences Corporation | Replacement heart valve prosthesis |
EP3541462A4 (en) | 2016-11-21 | 2020-06-17 | Neovasc Tiara Inc. | Methods and systems for rapid retraction of a transcatheter heart valve delivery system |
CN110392557A (en) | 2017-01-27 | 2019-10-29 | 耶拿阀门科技股份有限公司 | Heart valve simulation |
EP3366324A1 (en) * | 2017-02-22 | 2018-08-29 | Epygon | Product and method for the treatment of bioprosthetic tissues |
CN107007887B (en) * | 2017-02-27 | 2020-10-02 | 杭州启明医疗器械股份有限公司 | Cross-linked artificial biological valve and preparation method thereof |
CN106913909B (en) * | 2017-02-27 | 2020-09-01 | 杭州启明医疗器械股份有限公司 | Dry artificial biological valve and preparation method thereof |
US10631968B2 (en) | 2017-03-06 | 2020-04-28 | Edwards Lifesciences Corporation | Humidity-management packaging systems and methods |
EP3631062A4 (en) | 2017-05-31 | 2020-06-17 | Edwards Lifesciences Corporation | Collagen fibers and articles formed therefrom |
CN109125810A (en) * | 2017-06-19 | 2019-01-04 | 上海微创心通医疗科技有限公司 | A kind of preparation method of biovalve |
EP3645065B1 (en) | 2017-06-29 | 2022-09-28 | St. Jude Medical, Cardiology Division, Inc. | Method of preparing calcification-resistant bioprosthetic tissue |
CN111050702B (en) | 2017-07-13 | 2022-07-05 | 坦迪尼控股股份有限公司 | Prosthetic heart valve and apparatus and method for delivering a prosthetic heart valve |
EP3672530A4 (en) | 2017-08-25 | 2021-04-14 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
CN111031967B (en) | 2017-08-28 | 2022-08-09 | 坦迪尼控股股份有限公司 | Prosthetic heart valve with tether connection features |
US11395726B2 (en) | 2017-09-11 | 2022-07-26 | Incubar Llc | Conduit vascular implant sealing device for reducing endoleaks |
WO2019074838A2 (en) | 2017-10-13 | 2019-04-18 | Edwards Lifesciences Corporation | Method for sterilizing heart valves |
CN117481869A (en) | 2018-01-25 | 2024-02-02 | 爱德华兹生命科学公司 | Delivery system for assisting in recapture and repositioning of replacement valves after deployment |
DE112019002229T5 (en) | 2018-04-30 | 2021-02-25 | Edwards Lifesciences Corporation | Devices and methods for folding prosthetic implants |
CN109260517B (en) * | 2018-09-19 | 2020-10-30 | 杭州启明医疗器械股份有限公司 | Prefillable dry biological heart valve and preparation method thereof |
CN109172867B (en) * | 2018-09-19 | 2020-12-01 | 杭州启明医疗器械股份有限公司 | Pre-assembled biological heart valve capable of being rapidly rehydrated and preparation method thereof |
CN109820625A (en) * | 2018-09-30 | 2019-05-31 | 四川大学 | A kind of artificial bio-prosthetic valve membrane processing method of crosslinking |
EP3852683A1 (en) | 2018-11-01 | 2021-07-28 | Edwards Lifesciences Corporation | Transcatheter pulmonic regenerative valve |
JP7260930B2 (en) | 2018-11-08 | 2023-04-19 | ニオバスク ティアラ インコーポレイテッド | Ventricular deployment of a transcatheter mitral valve prosthesis |
EP3946163A4 (en) | 2019-04-01 | 2022-12-21 | Neovasc Tiara Inc. | Controllably deployable prosthetic valve |
CN113924065A (en) | 2019-04-10 | 2022-01-11 | 内奥瓦斯克迪亚拉公司 | Prosthetic valve with natural blood flow |
EP3972673A4 (en) | 2019-05-20 | 2023-06-07 | Neovasc Tiara Inc. | Introducer with hemostasis mechanism |
CN110152064B (en) * | 2019-06-04 | 2020-09-08 | 四川大学 | Heart valve modified by hydrophilic composite network lamination and preparation method thereof |
WO2020257643A1 (en) | 2019-06-20 | 2020-12-24 | Neovasc Tiara Inc. | Low profile prosthetic mitral valve |
CN110507856A (en) * | 2019-09-29 | 2019-11-29 | 四川大学 | A kind of full prepackage is dry to intervene aorta petal membrane material and preparation method thereof |
CR20210645A (en) | 2019-10-07 | 2022-05-12 | Edwards Lifesciences Corp | Balloons for prosthetic valve delivery apparatus and methods of assembly |
CN110585492B (en) * | 2019-10-12 | 2022-01-25 | 上海微创医疗器械(集团)有限公司 | Medical material and method for preparing anticoagulant coating on surface of medical material |
WO2021086608A1 (en) | 2019-10-31 | 2021-05-06 | Edwards Lifesciences Corporation | Blow molded balloon shoulder assembly for a transcatheter delivery device |
EP3831343B1 (en) | 2019-12-05 | 2024-01-31 | Tendyne Holdings, Inc. | Braided anchor for mitral valve |
CN110917399A (en) * | 2019-12-09 | 2020-03-27 | 沛嘉医疗科技(苏州)有限公司 | Anti-calcification method for biomaterial and biomaterial |
CN114258310A (en) * | 2019-12-09 | 2022-03-29 | 爱德华兹生命科学公司 | Bioprosthetic tissue preparation |
CN110917398A (en) * | 2019-12-09 | 2020-03-27 | 沛嘉医疗科技(苏州)有限公司 | Method for oxidation resistance of biomaterial and biomaterial |
US11648114B2 (en) | 2019-12-20 | 2023-05-16 | Tendyne Holdings, Inc. | Distally loaded sheath and loading funnel |
US11951002B2 (en) | 2020-03-30 | 2024-04-09 | Tendyne Holdings, Inc. | Apparatus and methods for valve and tether fixation |
CN111420120A (en) * | 2020-05-28 | 2020-07-17 | 四川大学 | Biological valve with anticoagulation and anti-calcification functions and preparation method thereof |
CN111569152A (en) * | 2020-05-28 | 2020-08-25 | 四川大学 | Biological valve with anticoagulation and calcification resistance and preparation method thereof |
CN111658825B (en) * | 2020-06-15 | 2021-03-30 | 四川大学 | Valve material with long-acting antithrombotic performance and preparation method thereof |
CN111658824B (en) * | 2020-06-15 | 2021-03-30 | 四川大学 | Valve membrane material with synergistic anticoagulation and anti-calcification functions and preparation method thereof |
CN111701079A (en) * | 2020-06-24 | 2020-09-25 | 四川大学 | Biological valve and treatment method thereof |
CN111701077B (en) * | 2020-06-24 | 2021-05-11 | 四川大学 | Valve with antithrombotic and anticalcification functions and preparation method and application thereof |
EP4199860A1 (en) | 2020-08-19 | 2023-06-28 | Tendyne Holdings, Inc. | Fully-transseptal apical pad with pulley for tensioning |
WO2022132569A1 (en) | 2020-12-18 | 2022-06-23 | Edwards Lifesciences Corporation | Storage jar assembly for aprosthetic heart valve |
CN114652893A (en) * | 2020-12-23 | 2022-06-24 | 上海微创心通医疗科技有限公司 | Method for treating bioprosthetic tissue and bioprosthetic heart valve |
CN114681673B (en) * | 2020-12-31 | 2023-05-23 | 杭州启明医疗器械股份有限公司 | Crease-resistant dehydrated crosslinking biological material and preparation method and application thereof |
KR20240017905A (en) | 2021-06-07 | 2024-02-08 | 에드워즈 라이프사이언시스 코포레이션 | Valve leaflets and leaflet separators for artificial valves |
WO2022266065A1 (en) | 2021-06-15 | 2022-12-22 | Edwards Lifesciences Corporation | Prosthetic valve assemblies |
CN113786515B (en) * | 2021-08-17 | 2022-10-11 | 中南大学湘雅二医院 | Method for treating cross-linked biological tissue |
IT202100025796A1 (en) * | 2021-10-08 | 2023-04-08 | Biocompatibility Innovation Srl | METHOD FOR THE PREPARATION OF SURFACES, IN PARTICULAR OF HEART PROSTHESES |
WO2023057947A1 (en) * | 2021-10-06 | 2023-04-13 | Biocompatibility Innovation S.r.l. | A method for the preparation of surfaces, particularly of cardiac prosthesis |
WO2023086650A1 (en) | 2021-11-15 | 2023-05-19 | Edwards Lifesciences Corporation | Prosthetic valves with wider outflow cells |
CN114748697B (en) * | 2021-11-17 | 2023-03-21 | 四川大学 | Double-bond post-crosslinked biological valve material and preparation and application thereof |
WO2023183441A1 (en) | 2022-03-23 | 2023-09-28 | Edwards Lifesciences Corporation | Prosthetic valves with valvular structures retained between two frames |
CN220158478U (en) | 2022-04-07 | 2023-12-12 | 爱德华兹生命科学公司 | Packaging assembly for storing prosthetic heart valves |
WO2023249885A1 (en) | 2022-06-23 | 2023-12-28 | Edwards Lifesciences Corporation | Prosthetic valves with information indicators |
WO2023249884A1 (en) | 2022-06-24 | 2023-12-28 | Edwards Lifesciences Corporation | Prosthetic valves with support arms |
WO2024006230A1 (en) | 2022-06-27 | 2024-01-04 | Edwards Lifesciences Corporation | Leaflet perforation tools and associated methods |
CN117339019A (en) * | 2022-06-28 | 2024-01-05 | 江苏臻亿医疗科技有限公司 | Biological tissue treatment method and medical material |
WO2024025897A1 (en) | 2022-07-27 | 2024-02-01 | Edwards Lifesciences Corporation | Balloon assemblies with inflatable toroid balloons |
WO2024030290A1 (en) | 2022-08-01 | 2024-02-08 | Edwards Lifesciences Corporation | Inflatable balloons with flow channels |
WO2024050043A1 (en) | 2022-09-02 | 2024-03-07 | Edwards Lifesciences Corporation | Prosthetic valves with non-uniform valvular structures |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000032252A1 (en) * | 1998-11-27 | 2000-06-08 | University Of Sheffield | Skin composites |
US20030135284A1 (en) * | 1998-06-30 | 2003-07-17 | Katrina Crouch | Plasticized bone grafts and methods of making and using same |
US20060159641A1 (en) * | 2002-01-25 | 2006-07-20 | Biomedical Design, Inc. | Variably crosslinked tissue |
US20060217805A1 (en) * | 2005-03-25 | 2006-09-28 | Dove Jeffrey S | Treatment of bioprosthetic tissues to mitigate post implantation calcification |
Family Cites Families (268)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2567929A (en) | 1951-09-18 | Process for preserving plant tissues | ||
US2393580A (en) | 1942-03-31 | 1946-01-22 | Edwin C Weiskopf | Method of preparing tissue |
US2484813A (en) | 1945-06-06 | 1949-10-18 | John O Bower | Spun suture |
US3982587A (en) * | 1974-11-20 | 1976-09-28 | Stewart-Warner Corporation | Vehicular radiator assembly |
IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
US4067091A (en) | 1976-11-15 | 1978-01-10 | Backman Philip E | Method of preparing human remains for storage |
US4120991A (en) | 1976-12-10 | 1978-10-17 | Technicon Instruments Corporation | Process for mounting tissue sections with an U.V. light curable mounting medium |
US4205059A (en) | 1977-03-09 | 1980-05-27 | Hagens Gunther Von | Animal and vegetal tissues permanently preserved by synthetic resin impregnation |
CA1087101A (en) | 1977-08-05 | 1980-10-07 | Cesar Romero-Sierra | Freeze dried biological specimens |
US4197658A (en) | 1978-05-12 | 1980-04-15 | Fts Systems, Inc. | Tissue freeze dryer |
US4328256A (en) | 1978-08-18 | 1982-05-04 | Queen's University At Kingston | Preservation of green plant tissues |
DE2914181C2 (en) | 1979-04-07 | 1982-06-16 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | Method and device for drying temperature-sensitive goods in the pharmaceutical and food industries |
US4294753A (en) | 1980-08-04 | 1981-10-13 | The Regents Of The University Of California | Bone morphogenetic protein process |
US4378224A (en) | 1980-09-19 | 1983-03-29 | Nimni Marcel E | Coating for bioprosthetic device and method of making same |
US4323358A (en) | 1981-04-30 | 1982-04-06 | Vascor, Inc. | Method for inhibiting mineralization of natural tissue during implantation |
US4372743A (en) | 1981-06-22 | 1983-02-08 | American Hospital Supply Corp. | Low-pressure fixation of valvular tissue intended for implantation |
US4350492A (en) | 1981-08-24 | 1982-09-21 | Vascor, Inc. | Method for preparing tissue heart valve |
FR2523810B1 (en) | 1982-03-23 | 1988-11-25 | Carpentier Alain | ORGANIC GRAFT FABRIC AND PROCESS FOR ITS PREPARATION |
US4481009A (en) | 1982-05-13 | 1984-11-06 | American Hospital Supply Corporation | Polymer incorporation into implantable biological tissue to inhibit calcification |
US4402697A (en) | 1982-08-25 | 1983-09-06 | Extracorporeal Medical Specialties, Inc. | Method for inhibiting mineralization of natural tissue during implantation |
US4405327A (en) | 1982-08-25 | 1983-09-20 | Extracorporeal Medical Specialties, Inc. | Method for inhibiting mineralization of natural tissue during implantation |
JPS60500014A (en) | 1982-11-12 | 1985-01-10 | バツクスター トラベノル ラボラトリーズ インコーポレーテツド | Chemical sterilization of biological tissue ready for transplantation |
US5215541A (en) | 1982-11-12 | 1993-06-01 | Baxter International Inc. | Surfactant treatment of implantable biological tissue to inhibit calcification |
US4885005A (en) | 1982-11-12 | 1989-12-05 | Baxter International Inc. | Surfactant treatment of implantable biological tissue to inhibit calcification |
US4599084A (en) | 1983-05-24 | 1986-07-08 | American Hospital Supply Corp. | Method of using biological tissue to promote even bone growth |
IT1159433B (en) | 1983-07-25 | 1987-02-25 | Sorin Biomedica Spa | PROCEDURE AND EQUIPMENT FOR THE MANUFACTURE OF VALVE FLAPS FOR CARDIAC VALVE PROSTHESIS AND CARDIAC VALVE PROSTHESIS PROVIDED WITH SUCH FLAPS |
IL69333A (en) * | 1983-07-26 | 1986-04-29 | Biolog Ind | Process for plant tissue culture propagation |
US4676070A (en) | 1984-11-30 | 1987-06-30 | The Board Of Regents, The University Of Texas | Apparatus and method for cryopreparing biological tissue |
US5024830A (en) | 1983-08-23 | 1991-06-18 | The Board Of Regents, The University Of Texas | Method for cryopreparing biological tissue for ultrastructural analysis |
US4865871A (en) | 1983-08-23 | 1989-09-12 | Board Of Regents The University Of Texas System | Method for cryopreparing biological tissue |
WO1987000196A1 (en) | 1985-07-09 | 1987-01-15 | Quadrant Bioresources Limited | Protection of proteins and the like |
US4753652A (en) | 1984-05-04 | 1988-06-28 | Children's Medical Center Corporation | Biomaterial implants which resist calcification |
GB8413319D0 (en) | 1984-05-24 | 1984-06-27 | Oliver Roy Frederick | Biological material |
EP0169259A1 (en) | 1984-07-25 | 1986-01-29 | Surgical Patent Products Inc. Ltd. | Vascular prostheses for dry preservation, method of conditioning and their use in surgery |
US4553974A (en) | 1984-08-14 | 1985-11-19 | Mayo Foundation | Treatment of collagenous tissue with glutaraldehyde and aminodiphosphonate calcification inhibitor |
IT1180531B (en) | 1984-09-21 | 1987-09-23 | Ge Sv In Srl | BICUSPID HEART VALVE PROSTHESIS |
US5011913A (en) | 1985-06-28 | 1991-04-30 | The Procter & Gamble Company | Diphosphonate-derivatized macromolecules |
US4755593A (en) * | 1985-07-24 | 1988-07-05 | Lauren Mark D | Novel biomaterial of cross-linked peritoneal tissue |
US4729139A (en) | 1985-11-05 | 1988-03-08 | Baxter Travenol | Selective incorporation of a polymer into implantable biological tissue to inhibit calcification |
US4770665A (en) | 1985-11-05 | 1988-09-13 | American Hospital Supply Corporation | Elastomeric polymer incorporation into implantable biological tissue to inhibit calcification |
DE3541478A1 (en) | 1985-11-23 | 1987-05-27 | Beiersdorf Ag | HEART VALVE PROSTHESIS AND METHOD FOR THE PRODUCTION THEREOF |
US5904718A (en) | 1986-03-27 | 1999-05-18 | Biocoll Laboratories, Inc. | Delayed drug delivery system |
US5108923A (en) | 1986-04-25 | 1992-04-28 | Collaborative Research, Inc. | Bioadhesives for cell and tissue adhesion |
SE455268B (en) | 1986-05-23 | 1988-07-04 | Moelnlycke Ab | Needle PARTY TAPE |
GB8618374D0 (en) | 1986-07-28 | 1986-09-03 | Hsc Res Dev Corp | Biological vascular prostheses |
US4786287A (en) | 1986-10-10 | 1988-11-22 | Baxter Travenol Laboratories | Process for decreasing residual aldehyde levels in implantable bioprosthetic tissue |
US5044165A (en) | 1986-12-03 | 1991-09-03 | Board Of Regents, The University Of Texas | Cryo-slammer |
US4838888A (en) | 1987-04-17 | 1989-06-13 | Baxter Travenol Laboratories, Inc. | Calcification mitigation of implantable bioprostheses |
FR2617855B1 (en) | 1987-07-08 | 1992-02-21 | Bioetica Sa | PROCESS FOR CROSSLINKING COLLAGEN BY INTRODUCING AZID GROUPS AS WELL AS TISSUES AND BIOMATERIALS OBTAINED BY IMPLEMENTING THE PROCESS |
US5147514A (en) | 1987-08-02 | 1992-09-15 | University Of North Carolina | Process for cross-linking collagenous material and resulting product |
US5149621A (en) | 1987-08-21 | 1992-09-22 | Cryolife, Inc. & Medical Univ. Of South Carolina | Kit for cryopreserving blood vessels |
JP2529112B2 (en) | 1987-08-31 | 1996-08-28 | 株式会社 高研 | Biological valve |
US4994237A (en) | 1987-10-02 | 1991-02-19 | The Beth Israel Hospital Association | Microwave preservation of bioprostheses |
GB8801338D0 (en) | 1988-01-21 | 1988-02-17 | Quadrant Bioresources Ltd | Preservation of viruses |
US4976733A (en) | 1988-02-03 | 1990-12-11 | Biomedical Design, Inc. | Prevention of prosthesis calcification |
US5094661A (en) | 1988-04-01 | 1992-03-10 | The University Of Michigan | Calcification-resistant materials and methods of making same through use of trivalent aluminum |
US5368608A (en) | 1988-04-01 | 1994-11-29 | University Of Michigan, The Board Of Regents | Calcification-resistant materials and methods of making same through use of multivalent cations |
US5746775A (en) | 1988-04-01 | 1998-05-05 | The Board Of Regent6S Of The University Of Michigan | Method of making calcification-resistant bioprosthetic tissue |
US4975526A (en) | 1989-02-23 | 1990-12-04 | Creative Biomolecules, Inc. | Bone collagen matrix for zenogenic implants |
US4994030A (en) | 1988-06-28 | 1991-02-19 | Osteotech, Inc. | Reconstitution of human bone and tissue |
DE3834545A1 (en) | 1988-10-11 | 1990-04-12 | Rau Guenter | FLEXIBLE LOCKING ORGAN, PARTICULARLY HEART VALVE, AND METHOD FOR PRODUCING THE SAME |
US5002566A (en) | 1989-02-17 | 1991-03-26 | Baxter International Inc. | Calcification mitigation of bioprosthetic implants |
US5068100A (en) | 1989-03-09 | 1991-11-26 | The Procter & Gamble Company | Anticalculus compositions |
US5051401A (en) | 1989-04-07 | 1991-09-24 | University Of South Alabama | Inhibition of mineral deposition by phosphorylated and related polyanionic peptides |
AU626686B2 (en) | 1989-06-09 | 1992-08-06 | Medtronic, Inc. | Dynamic fixation of porcine aortic valves |
CA2022480C (en) | 1989-08-02 | 2001-02-27 | Gerald L. Mechanic | Process for cross-linking collagenous materials and resulting product |
US5154007A (en) | 1989-08-17 | 1992-10-13 | Board Of Regents University Of Texas System | Method and apparatus for cryopreparing biological tissue |
US5290558A (en) | 1989-09-21 | 1994-03-01 | Osteotech, Inc. | Flowable demineralized bone powder composition and its use in bone repair |
WO1991017724A1 (en) | 1990-05-17 | 1991-11-28 | Harbor Medical Devices, Inc. | Medical device polymer |
US8067149B2 (en) | 1990-09-12 | 2011-11-29 | Lifecell Corporation | Acellular dermal matrix and method of use thereof for grafting |
US5336616A (en) | 1990-09-12 | 1994-08-09 | Lifecell Corporation | Method for processing and preserving collagen-based tissues for transplantation |
US5200399A (en) | 1990-09-14 | 1993-04-06 | Boyce Thompson Institute For Plant Research, Inc. | Method of protecting biological materials from destructive reactions in the dry state |
US5104405A (en) | 1991-02-21 | 1992-04-14 | The University Of Southern California | Process for improving the biostability of tissue implant devices and bioprosthetic implants so produced |
IT1245750B (en) | 1991-05-24 | 1994-10-14 | Sorin Biomedica Emodialisi S R | CARDIAC VALVE PROSTHESIS, PARTICULARLY FOR REPLACING THE AORTIC VALVE |
US6503277B2 (en) | 1991-08-12 | 2003-01-07 | Peter M. Bonutti | Method of transplanting human body tissue |
US5329846A (en) | 1991-08-12 | 1994-07-19 | Bonutti Peter M | Tissue press and system |
US5998483A (en) | 1991-09-20 | 1999-12-07 | Camiener; Gerald W. | Glyoxal-containing preservative compositions |
US5476516A (en) | 1992-03-13 | 1995-12-19 | Albert Einstein College Of Medicine Of Yeshiva University | Anticalcification treatment for aldehyde-tanned biological tissue |
US5257662A (en) * | 1992-03-27 | 1993-11-02 | The Allen Group Inc. | Heat exchanger assembly |
US5296583A (en) | 1992-07-09 | 1994-03-22 | University Of Michigan | Calcification-resistant synthetic biomaterials |
US5436291A (en) | 1992-07-09 | 1995-07-25 | University Of Michigan, The Board Of . . . | Calcification-resistant synthetic biomaterials |
US5437287A (en) | 1992-08-17 | 1995-08-01 | Carbomedics, Inc. | Sterilization of tissue implants using iodine |
US5522893A (en) | 1993-03-12 | 1996-06-04 | American Dental Association Health Foundation | Calcium phosphate hydroxyapatite precursor and methods for making and using the same |
US5509932A (en) | 1993-04-08 | 1996-04-23 | Keogh; James R. | Fixed tissue medical devices comprising albumin-binding dyes |
US5507813A (en) | 1993-12-09 | 1996-04-16 | Osteotech, Inc. | Shaped materials derived from elongate bone particles |
US5460962A (en) | 1994-01-04 | 1995-10-24 | Organogenesis Inc. | Peracetic acid sterilization of collagen or collagenous tissue |
EP0663214B1 (en) | 1994-01-18 | 1999-03-31 | Sci-Can, A Division Of Lux And Zwingenberger Ltd. | Assembly for the steam sterilization of surgical instruments, implants and the like |
US5447536A (en) | 1994-02-17 | 1995-09-05 | Biomedical Design, Inc. | Method for fixation of biological tissue |
US6203755B1 (en) | 1994-03-04 | 2001-03-20 | St. Jude Medical, Inc. | Electron beam sterilization of biological tissues |
KR100365573B1 (en) | 1994-03-14 | 2004-08-25 | 크라이어라이프, 인크. | Transplantation tissue and its manufacturing method |
US5595571A (en) | 1994-04-18 | 1997-01-21 | Hancock Jaffe Laboratories | Biological material pre-fixation treatment |
CA2186374A1 (en) | 1994-04-29 | 1995-11-09 | William Carl Bruchman | Improved blood contact surfaces employing natural subendothelial matrix and method for making and using the same |
EP0757562A1 (en) | 1994-04-29 | 1997-02-12 | W.L. Gore & Associates, Inc. | Improved blood contact surfaces using endothelium on a subendothelial extracellular matrix |
US5558875A (en) | 1994-06-06 | 1996-09-24 | Wang; Su | Method of preparing collagenous tissue |
EP0713400A1 (en) | 1994-06-15 | 1996-05-29 | St.Jude Medical, Inc | Enhanced cross-linking of natural tissues |
DE4422555C1 (en) | 1994-06-28 | 1995-08-10 | Daimler Benz Ag | Rack=and=pinion steering with servomotor support |
KR0131046B1 (en) | 1994-07-13 | 1998-04-14 | 김은영 | Calcification-resistant tissue heart valve |
US5554184A (en) * | 1994-07-27 | 1996-09-10 | Machiraju; Venkat R. | Heart valve |
DE69523074T2 (en) | 1994-07-29 | 2002-06-06 | Edwards Lifesciences Corp | METHOD FOR TREATING IMPLANTABLE BIOLOGICAL TISSUES TO REDUCE CALCIFICATION |
US5931969A (en) | 1994-07-29 | 1999-08-03 | Baxter International Inc. | Methods and apparatuses for treating biological tissue to mitigate calcification |
USRE40570E1 (en) | 1994-07-29 | 2008-11-11 | Edwards Lifesciences Corporation | Apparatuses and methods for treating biological tissue to mitigate calcification |
US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
US6586006B2 (en) | 1994-08-04 | 2003-07-01 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
US5556379A (en) | 1994-08-19 | 1996-09-17 | Lifenet Research Foundation | Process for cleaning large bone grafts and bone grafts produced thereby |
US5549666A (en) | 1994-09-02 | 1996-08-27 | Baxter International Inc. | Natural tissue valve prostheses having variably complaint leaflets |
US5674298A (en) | 1994-10-21 | 1997-10-07 | The Board Of Regents Of The University Of Michigan | Calcification-resistant bioprosthetic tissue and methods of making same |
US6372228B1 (en) | 1994-11-15 | 2002-04-16 | Kenton W. Gregory | Method of producing elastin, elastin-based biomaterials and tropoelastin materials |
AU692330B2 (en) | 1994-12-30 | 1998-06-04 | National University Of Singapore, The | Method for reducing calcification of biological tissue used in implantable bioprostheses |
ZA963151B (en) | 1995-04-19 | 1997-04-24 | St Jude Medical | Matrix substrate for a viable body tissue-derived prosthesis and method for making the same |
US6231608B1 (en) | 1995-06-07 | 2001-05-15 | Crosscart, Inc. | Aldehyde and glycosidase-treated soft and bone tissue xenografts |
US5913900A (en) | 1995-06-07 | 1999-06-22 | Corsscart, Inc. | Substantially native meniscal cartilage heterografts |
US5865849A (en) | 1995-06-07 | 1999-02-02 | Crosscart, Inc. | Meniscal heterografts |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US5902338A (en) | 1995-09-15 | 1999-05-11 | Crosscart, Inc. | Anterior cruciate ligament heterograft |
US5782915A (en) | 1995-09-15 | 1998-07-21 | Stone; Kevin R. | Articular cartilage heterografts |
US5720894A (en) | 1996-01-11 | 1998-02-24 | The Regents Of The University Of California | Ultrashort pulse high repetition rate laser system for biological tissue processing |
US6193749B1 (en) | 1996-02-05 | 2001-02-27 | St. Jude Medical, Inc. | Calcification-resistant biomaterials |
US6302909B1 (en) | 1996-07-31 | 2001-10-16 | St. Jude Medical, Inc. | Calcification-resistant biomaterials |
IT1285308B1 (en) | 1996-03-12 | 1998-06-03 | Sorin Biomedica Cardio Spa | PROCEDURE FOR THE PREPARATION OF BIOLOGICAL MATERIAL FOR PLANT |
US5919472A (en) | 1996-03-19 | 1999-07-06 | Medtronic, Inc. | Treatment of aldehyde-fixed tissue |
US6024735A (en) | 1996-03-20 | 2000-02-15 | Lifenet Research Foundation | Process and composition for cleaning soft tissue grafts optionally attached to bone and soft tissue and bone grafts produced thereby |
US5945319A (en) | 1996-04-25 | 1999-08-31 | Medtronic, Inc. | Periodate oxidative method for attachment of biomolecules to medical device surfaces |
US5925552A (en) | 1996-04-25 | 1999-07-20 | Medtronic, Inc. | Method for attachment of biomolecules to medical devices surfaces |
US5928916A (en) | 1996-04-25 | 1999-07-27 | Medtronic, Inc. | Ionic attachment of biomolecules with a guanidino moiety to medical device surfaces |
IL118149A0 (en) | 1996-05-05 | 1996-09-12 | Rdc Rafael Dev Corp | Method for producing heart valves and heart valves produced by the method |
US5766520A (en) | 1996-07-15 | 1998-06-16 | Universal Preservation Technologies, Inc. | Preservation by foam formation |
US5645587A (en) | 1996-06-05 | 1997-07-08 | Chanda; Jyotirmay | Prevention of calcification and degeneration of biological tissue grafts for implantation in humans |
US5695820A (en) * | 1996-06-20 | 1997-12-09 | Hewlett-Packard Company | Method for alleviating marangoni flow-induced print defects in ink-jet printing |
SE506983C2 (en) | 1996-07-02 | 1998-03-09 | Akzo Nobel Nv | Orthoester based polymer, process for its preparation and use thereof |
US5782931A (en) | 1996-07-30 | 1998-07-21 | Baxter International Inc. | Methods for mitigating calcification and improving durability in glutaraldehyde-fixed bioprostheses and articles manufactured by such methods |
US6121041A (en) | 1996-07-31 | 2000-09-19 | St. Jude Medical, Inc. | Use of microorganisms for decellularizing bioprosthetic tissue |
AU3950297A (en) | 1996-08-21 | 1998-03-06 | Sulzer Vascutek Limited | Method of sterilising material for implantation |
US6666892B2 (en) * | 1996-08-23 | 2003-12-23 | Cook Biotech Incorporated | Multi-formed collagenous biomaterial medical device |
US6764509B2 (en) | 1996-09-06 | 2004-07-20 | Carbomedics Inc. | Prosthetic heart valve with surface modification |
US5782914A (en) | 1996-11-29 | 1998-07-21 | Bio-Vascular, Inc. | Method for preparing heterogeneous tissue grafts |
US5856172A (en) | 1997-01-03 | 1999-01-05 | Quality Technologies, Llc | Preservation of microorganisms in a vial with a cap comprising an immobilized desiccant |
US6506339B1 (en) | 1997-02-10 | 2003-01-14 | Biomedical Design, Inc. | Method of sterilization |
JP4271262B2 (en) | 1997-02-10 | 2009-06-03 | バイオメディカル デザイン インコーポレイテッド | Sterilization method |
US5856102A (en) | 1997-02-26 | 1999-01-05 | Bierke-Nelson; Diane Lynn | Home/self-storage to improve DNA banking |
US5865244A (en) * | 1997-03-25 | 1999-02-02 | Behr America, Inc. | Plastic header tank matrix and method of making same |
US5928281A (en) | 1997-03-27 | 1999-07-27 | Baxter International Inc. | Tissue heart valves |
WO1998046165A1 (en) | 1997-04-11 | 1998-10-22 | Cryolife, Inc. | Tissue decellularization |
US6206917B1 (en) | 1997-05-02 | 2001-03-27 | St. Jude Medical, Inc. | Differential treatment of prosthetic devices |
US5993844A (en) | 1997-05-08 | 1999-11-30 | Organogenesis, Inc. | Chemical treatment, without detergents or enzymes, of tissue to form an acellular, collagenous matrix |
US6156030A (en) | 1997-06-04 | 2000-12-05 | Y-Beam Technologies, Inc. | Method and apparatus for high precision variable rate material removal and modification |
US5987720A (en) | 1997-07-08 | 1999-11-23 | Yamamoto; William Shigeru | Portable tomb for resurrection from mummified tissue DNA |
US6117979A (en) | 1997-08-18 | 2000-09-12 | Medtronic, Inc. | Process for making a bioprosthetic device and implants produced therefrom |
US6166184A (en) | 1997-08-18 | 2000-12-26 | Medtronic Inc. | Process for making a bioprosthetic device |
US6613278B1 (en) | 1998-11-13 | 2003-09-02 | Regeneration Technologies, Inc. | Tissue pooling process |
US5862806A (en) | 1997-10-30 | 1999-01-26 | Mitroflow International, Inc. | Borohydride reduction of biological tissues |
US6267782B1 (en) | 1997-11-20 | 2001-07-31 | St. Jude Medical, Inc. | Medical article with adhered antimicrobial metal |
US6008292A (en) | 1997-12-02 | 1999-12-28 | Baxter International Inc. | Method for inhibiting calcification of aldehyde-fixed bioprosthetic materials |
US5921980A (en) | 1997-12-03 | 1999-07-13 | University Of Kentucky Research Foundation | Laser skin graft harvesting apparatus and related method |
US6254635B1 (en) | 1998-02-02 | 2001-07-03 | St. Jude Medical, Inc. | Calcification-resistant medical articles |
US6093530A (en) | 1998-02-06 | 2000-07-25 | Sulzer Carbomedics Inc. | Non-calcific biomaterial by glutaraldehyde followed by oxidative fixation |
US6251579B1 (en) | 1998-02-13 | 2001-06-26 | Sulzer Carbomedics Inc. | Oxidative stabilization of collagen containing materials |
US6383732B1 (en) | 1999-02-11 | 2002-05-07 | Crosscart, Inc. | Method of preparing xenograft heart valves |
US6258320B1 (en) | 1998-04-09 | 2001-07-10 | David H. Persing | Method for preservation of nucleic acids |
CA2335152C (en) | 1998-05-14 | 2008-11-18 | The Cleveland Clinic Foundation | Processing of implantable animal tissues for dry storage |
US6933326B1 (en) | 1998-06-19 | 2005-08-23 | Lifecell Coporation | Particulate acellular tissue matrix |
US6630001B2 (en) | 1998-06-24 | 2003-10-07 | International Heart Institute Of Montana Foundation | Compliant dehyrated tissue for implantation and process of making the same |
US6293970B1 (en) | 1998-06-30 | 2001-09-25 | Lifenet | Plasticized bone and soft tissue grafts and methods of making and using same |
US6734018B2 (en) | 1999-06-07 | 2004-05-11 | Lifenet | Process for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced |
US20030217415A1 (en) | 1998-06-30 | 2003-11-27 | Katrina Crouch | Plasticized bone grafts and methods of making and using same |
US6527979B2 (en) | 1999-08-27 | 2003-03-04 | Corazon Technologies, Inc. | Catheter systems and methods for their use in the treatment of calcified vascular occlusions |
US6394096B1 (en) | 1998-07-15 | 2002-05-28 | Corazon Technologies, Inc. | Method and apparatus for treatment of cardiovascular tissue mineralization |
US6156531A (en) | 1998-07-20 | 2000-12-05 | Sulzer Carbomedics Inc. | Cross-linking tissue with a compound having a C8 to C40 aliphatic chain |
US6448076B2 (en) | 1998-09-15 | 2002-09-10 | The Regents Of The University Of Michigan | Method for chemically acellularizing a biological tissue sample |
US6214054B1 (en) | 1998-09-21 | 2001-04-10 | Edwards Lifesciences Corporation | Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby |
US6334873B1 (en) | 1998-09-28 | 2002-01-01 | Autogenics | Heart valve having tissue retention with anchors and an outer sheath |
JP4663120B2 (en) | 1998-09-30 | 2011-03-30 | メドトロニック,インコーポレイテッド | Methods for reducing mineralization of tissues used in transplantation |
US6214055B1 (en) | 1998-10-30 | 2001-04-10 | Mures Cardiovascular Research, Inc. | Method and kit for rapid preparation of autologous tissue medical devices |
US6066160A (en) | 1998-11-23 | 2000-05-23 | Quickie Llc | Passive knotless suture terminator for use in minimally invasive surgery and to facilitate standard tissue securing |
US6375680B1 (en) | 1998-12-01 | 2002-04-23 | St. Jude Medical, Inc. | Substrates for forming synthetic tissues |
US6106555A (en) | 1998-12-15 | 2000-08-22 | Av Healing Llc | Method for tissue fixation |
US6364905B1 (en) | 1999-01-27 | 2002-04-02 | Sulzer Carbomedics Inc. | Tri-composite, full root, stentless valve |
US6267786B1 (en) | 1999-02-11 | 2001-07-31 | Crosscart, Inc. | Proteoglycan-reduced soft tissue xenografts |
CN100553678C (en) | 1999-02-22 | 2009-10-28 | 巴克斯特国际有限公司 | The factor VIII formulations of new albumin-free |
US6287338B1 (en) | 1999-03-10 | 2001-09-11 | Sulzer Carbomedics Inc. | Pre-stressing devices incorporating materials subject to stress softening |
US6177514B1 (en) | 1999-04-09 | 2001-01-23 | Sulzer Carbomedics Inc. | Blocked functional reagants for cross-linking biological tissues |
US6322593B1 (en) | 1999-04-09 | 2001-11-27 | Sulzer Carbomedics Inc. | Method for treating cross-linked biological tissues |
US6132986A (en) | 1999-04-23 | 2000-10-17 | Sulzer Carbomedics Inc. | Tissue crosslinking for bioprostheses using activated difunctional or polyfunctional acids |
US6328762B1 (en) | 1999-04-27 | 2001-12-11 | Sulzer Biologics, Inc. | Prosthetic grafts |
US6644642B1 (en) | 1999-05-25 | 2003-11-11 | Silverbrook Research Pty Ltd | Printed media parallel binder |
US6790229B1 (en) | 1999-05-25 | 2004-09-14 | Eric Berreklouw | Fixing device, in particular for fixing to vascular wall tissue |
US6174331B1 (en) | 1999-07-19 | 2001-01-16 | Sulzer Carbomedics Inc. | Heart valve leaflet with reinforced free margin |
US6312474B1 (en) | 1999-09-15 | 2001-11-06 | Bio-Vascular, Inc. | Resorbable implant materials |
US6352708B1 (en) | 1999-10-14 | 2002-03-05 | The International Heart Institute Of Montana Foundation | Solution and method for treating autologous tissue for implant operation |
DE60029300D1 (en) | 1999-10-20 | 2006-08-24 | Grain Processing Corp | COMPOSITIONS CONTAINING REDUCED MALTO OLIGOSACCHARIDE AS A PRESERVATIVE |
US6322994B1 (en) | 1999-11-04 | 2001-11-27 | Genetix Limited | Method of freeze-drying organisms |
US6479079B1 (en) | 1999-12-13 | 2002-11-12 | Sulzer Carbomedics Inc. | Anticalcification treatments for fixed biomaterials |
US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
US6376244B1 (en) | 1999-12-29 | 2002-04-23 | Children's Medical Center Corporation | Methods and compositions for organ decellularization |
US6471723B1 (en) | 2000-01-10 | 2002-10-29 | St. Jude Medical, Inc. | Biocompatible prosthetic tissue |
US6872226B2 (en) | 2001-01-29 | 2005-03-29 | 3F Therapeutics, Inc. | Method of cutting material for use in implantable medical device |
CN1404376A (en) | 2000-01-27 | 2003-03-19 | 3F治疗有限公司 | Prosthetic heart valve |
US6391538B1 (en) | 2000-02-09 | 2002-05-21 | The Children's Hospital Of Philadelphia | Stabilization of implantable bioprosthetic tissue |
US6610088B1 (en) | 2000-05-03 | 2003-08-26 | Shlomo Gabbay | Biologically covered heart valve prosthesis |
US6653062B1 (en) | 2000-07-26 | 2003-11-25 | Wisconsin Alumni Research Foundation | Preservation and storage medium for biological materials |
US6605667B1 (en) | 2000-09-08 | 2003-08-12 | Closure Medical Corporation | Antioxidant enriched adhesive compositions and storage containers therefor |
US6696074B2 (en) | 2000-12-04 | 2004-02-24 | Tei Biosciences, Inc. | Processing fetal or neo-natal tissue to produce a scaffold for tissue engineering |
US20020111532A1 (en) | 2000-12-19 | 2002-08-15 | Pathak Chandrashekhar P. | Tris(hydroxymethyl)phosphino compounds as tissue crosslinking agents |
US6468660B2 (en) | 2000-12-29 | 2002-10-22 | St. Jude Medical, Inc. | Biocompatible adhesives |
US20020091441A1 (en) | 2001-01-05 | 2002-07-11 | Guzik Donald S. | Focused beam cutting of materials |
US6377143B1 (en) | 2001-03-16 | 2002-04-23 | Eaton Corporation | Weld-free contact system for electromagnetic contactors |
US7078163B2 (en) | 2001-03-30 | 2006-07-18 | Medtronic, Inc. | Process for reducing mineralization of tissue used in transplantation |
GB2375771A (en) | 2001-05-24 | 2002-11-27 | Univ Leeds | Decellularisation of tissue implant material |
US6589591B1 (en) | 2001-07-10 | 2003-07-08 | Baylor College Of Medicine | Method for treating medical devices using glycerol and an antimicrobial agent |
GB0125925D0 (en) | 2001-10-29 | 2001-12-19 | Univ Glasgow | Mitral valve prosthesis |
US7201771B2 (en) | 2001-12-27 | 2007-04-10 | Arbor Surgical Technologies, Inc. | Bioprosthetic heart valve |
US7189258B2 (en) | 2002-01-02 | 2007-03-13 | Medtronic, Inc. | Heart valve system |
US6878168B2 (en) | 2002-01-03 | 2005-04-12 | Edwards Lifesciences Corporation | Treatment of bioprosthetic tissues to mitigate post implantation calcification |
US8308797B2 (en) | 2002-01-04 | 2012-11-13 | Colibri Heart Valve, LLC | Percutaneously implantable replacement heart valve device and method of making same |
US7141064B2 (en) | 2002-05-08 | 2006-11-28 | Edwards Lifesciences Corporation | Compressed tissue for heart valve leaflets |
US7578843B2 (en) | 2002-07-16 | 2009-08-25 | Medtronic, Inc. | Heart valve prosthesis |
US6908591B2 (en) | 2002-07-18 | 2005-06-21 | Clearant, Inc. | Methods for sterilizing biological materials by irradiation over a temperature gradient |
US7008763B2 (en) | 2002-09-23 | 2006-03-07 | Cheung David T | Method to treat collagenous connective tissue for implant remodeled by host cells into living tissue |
US7189259B2 (en) | 2002-11-26 | 2007-03-13 | Clemson University | Tissue material and process for bioprosthesis |
WO2004082536A1 (en) | 2003-03-20 | 2004-09-30 | Aortech International Plc | Valve |
US20040193259A1 (en) | 2003-03-25 | 2004-09-30 | Shlomo Gabbay | Sizing apparatus for cardiac prostheses and method of using same |
US20050211680A1 (en) | 2003-05-23 | 2005-09-29 | Mingwei Li | Systems and methods for laser texturing of surfaces of a substrate |
IL156626A (en) | 2003-06-24 | 2009-12-24 | Yeda Res & Dev | System for selective cell destruction |
US9022037B2 (en) | 2003-08-11 | 2015-05-05 | Raydiance, Inc. | Laser ablation method and apparatus having a feedback loop and control unit |
US7143769B2 (en) | 2003-08-11 | 2006-12-05 | Richard Stoltz | Controlling pulse energy of an optical amplifier by controlling pump diode current |
US7367969B2 (en) | 2003-08-11 | 2008-05-06 | Raydiance, Inc. | Ablative material removal with a preset removal rate or volume or depth |
US7053051B2 (en) | 2003-10-28 | 2006-05-30 | Medtronic, Inc. | Methods of preparing crosslinked materials and bioprosthetic devices |
US7955788B2 (en) | 2003-10-30 | 2011-06-07 | Medtronic, Inc. | Bioprosthetic tissue preparation with synthetic hydrogels |
US7648676B2 (en) | 2004-04-20 | 2010-01-19 | Rti Biologics, Inc. | Process and apparatus for treating implants comprising soft tissue |
WO2006026325A2 (en) | 2004-08-26 | 2006-03-09 | Pathak Chandrashekhar P | Implantable tissue compositions and method |
US20060110370A1 (en) | 2004-11-23 | 2006-05-25 | Pathak Chandrashenkhar P | Treatments for reduction of cytotoxicity and viral contamination of implantable medical devices |
WO2006066327A1 (en) | 2004-12-24 | 2006-06-29 | Celxcel Pty Ltd | An implantable biomaterial and a method of producing same |
US20060177426A1 (en) | 2005-02-09 | 2006-08-10 | Cecil Gibson | Method of preserving lyophilized microorganisms for transport, storage and recovery of viable microorganisms |
JP4975013B2 (en) | 2005-03-11 | 2012-07-11 | ウエイク・フオレスト・ユニバーシテイ・ヘルス・サイエンシズ | Manufacture of heart valves with engineered tissue |
US20060217804A1 (en) | 2005-03-25 | 2006-09-28 | Dove Jeffrey S | Treatment of bioprosthetic tissues to mitigate post implantation calcification |
US7914569B2 (en) | 2005-05-13 | 2011-03-29 | Medtronics Corevalve Llc | Heart valve prosthesis and methods of manufacture and use |
US7238200B2 (en) | 2005-06-03 | 2007-07-03 | Arbor Surgical Technologies, Inc. | Apparatus and methods for making leaflets and valve prostheses including such leaflets |
US20070292459A1 (en) | 2005-07-18 | 2007-12-20 | Cooper Sarah M | Halloysite microtubule processes, structures, and compositions |
US8470022B2 (en) | 2005-08-31 | 2013-06-25 | Cook Biotech Incorporated | Implantable valve |
US7682304B2 (en) | 2005-09-21 | 2010-03-23 | Medtronic, Inc. | Composite heart valve apparatus manufactured using techniques involving laser machining of tissue |
EP2004095B1 (en) | 2006-03-28 | 2019-06-12 | Medtronic, Inc. | Prosthetic cardiac valve formed from pericardium material and methods of making same |
US10876193B2 (en) | 2006-09-29 | 2020-12-29 | University Of Rochester | Nanostructured materials, methods, and applications |
US20080299408A1 (en) | 2006-09-29 | 2008-12-04 | University Of Rochester | Femtosecond Laser Pulse Surface Structuring Methods and Materials Resulting Therefrom |
EP2077718B2 (en) | 2006-10-27 | 2022-03-09 | Edwards Lifesciences Corporation | Biological tissue for surgical implantation |
US8105375B2 (en) | 2007-01-19 | 2012-01-31 | The Cleveland Clinic Foundation | Method for implanting a cardiovascular valve |
US9101691B2 (en) | 2007-06-11 | 2015-08-11 | Edwards Lifesciences Corporation | Methods for pre-stressing and capping bioprosthetic tissue |
FR2917625B1 (en) | 2007-06-20 | 2009-09-18 | Perouse Soc Par Actions Simpli | TREATMENT OF IMPLANTABLE MEDICAL DEVICES RESISTANT TO CALCIFICATION |
US8357387B2 (en) * | 2007-12-21 | 2013-01-22 | Edwards Lifesciences Corporation | Capping bioprosthetic tissue to reduce calcification |
WO2009129483A1 (en) | 2008-04-17 | 2009-10-22 | Musculoskeletal Transplant Foundation | Ultrashort pulse laser applications |
US8136218B2 (en) | 2008-04-29 | 2012-03-20 | Medtronic, Inc. | Prosthetic heart valve, prosthetic heart valve assembly and method for making same |
EP3799839A1 (en) | 2008-06-06 | 2021-04-07 | Edwards Lifesciences Corporation | Low profile transcatheter heart valve |
US7967138B2 (en) * | 2009-04-06 | 2011-06-28 | Medtronic Vascular, Inc. | Packaging systems for percutaneously deliverable bioprosthetic valves |
WO2010141948A1 (en) * | 2009-06-05 | 2010-12-09 | Tyco Fire Products Lp | Concealed sprinkler |
SG10201501500TA (en) | 2010-03-01 | 2015-04-29 | Colibri Heart Valve Llc | Percutaneously deliverable heart valve and methods associated therewith |
EP2542668A2 (en) | 2010-03-01 | 2013-01-09 | Colibri Heart Valve LLC | Tissue for prosthetic implants and grafts, and methods associated therewith |
US8679404B2 (en) | 2010-03-05 | 2014-03-25 | Edwards Lifesciences Corporation | Dry prosthetic heart valve packaging system |
NZ602706A (en) | 2010-03-23 | 2014-02-28 | Edwards Lifesciences Corp | Methods of conditioning sheet bioprosthetic tissue |
BR112012029896A2 (en) | 2010-05-25 | 2017-06-20 | Jenavalve Tech Inc | prosthetic heart valve for stent graft and stent graft |
IT1400544B1 (en) | 2010-06-09 | 2013-06-11 | Sorin Biomedica Cardio Srl | PROCESS OF DETOXIFICATION OF BIOLOGICAL FABRIC. |
IT1400545B1 (en) | 2010-06-09 | 2013-06-11 | Sorin Biomedica Cardio Srl | PROCEDURE FOR THE PREPARATION OF BIOLOGICAL FABRIC FOR BIOLOGICAL PROSTHESIS. |
US8906601B2 (en) | 2010-06-17 | 2014-12-09 | Edwardss Lifesciences Corporation | Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates |
US8377143B2 (en) | 2010-07-06 | 2013-02-19 | Cryolife, Inc. | Tissue implants for implantation and methods for preparing the same |
US8475827B2 (en) | 2010-07-06 | 2013-07-02 | Cryolife, Inc. | Tissue implants for implantation and methods for preparing the same |
WO2012027515A2 (en) | 2010-08-24 | 2012-03-01 | Southern Lights Ventures 2002 Limited | Biomaterials with enhanced properties and devices made therefrom |
AU2011305153A1 (en) | 2010-09-23 | 2013-05-02 | Colibri Heart Valve Llc | Percutaneously deliverable heart or blood vessel valve with frame having abluminally situated tissue membrane |
US9351829B2 (en) | 2010-11-17 | 2016-05-31 | Edwards Lifesciences Corporation | Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability |
JP2014507179A (en) | 2010-12-14 | 2014-03-27 | コリブリ ハート バルブ エルエルシー | Percutaneously deliverable heart valve including folded membrane cusps with integrated leaflets |
EP2729094A4 (en) | 2011-07-08 | 2015-08-05 | Univ California | Method of using medical implants |
US20130122583A1 (en) | 2011-11-10 | 2013-05-16 | Celxcel Pty Ltd | Sterilization process |
-
2008
- 2008-12-18 US US12/338,872 patent/US8357387B2/en active Active
- 2008-12-19 CN CN201410014350.3A patent/CN103705980B/en active Active
- 2008-12-19 CN CN200880126930.4A patent/CN101965205B/en active Active
- 2008-12-19 EP EP13003386.3A patent/EP2647393B1/en active Active
- 2008-12-19 EP EP08866741.5A patent/EP2234657B1/en active Active
- 2008-12-19 EP EP18197247.2A patent/EP3453409B1/en active Active
- 2008-12-19 CA CA2710366A patent/CA2710366C/en active Active
- 2008-12-19 WO PCT/US2008/013879 patent/WO2009085199A2/en active Application Filing
-
2010
- 2010-05-11 US US12/777,994 patent/US7972376B1/en active Active
-
2013
- 2013-01-18 US US13/745,496 patent/US8748490B2/en active Active
- 2013-12-23 US US14/139,367 patent/US9029418B2/en active Active
-
2015
- 2015-05-08 US US14/707,970 patent/US9320830B2/en active Active
-
2016
- 2016-04-25 US US15/138,123 patent/US10188511B2/en active Active
-
2019
- 2019-01-21 US US16/253,051 patent/US10966822B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030135284A1 (en) * | 1998-06-30 | 2003-07-17 | Katrina Crouch | Plasticized bone grafts and methods of making and using same |
WO2000032252A1 (en) * | 1998-11-27 | 2000-06-08 | University Of Sheffield | Skin composites |
US20060159641A1 (en) * | 2002-01-25 | 2006-07-20 | Biomedical Design, Inc. | Variably crosslinked tissue |
US20060217805A1 (en) * | 2005-03-25 | 2006-09-28 | Dove Jeffrey S | Treatment of bioprosthetic tissues to mitigate post implantation calcification |
Non-Patent Citations (2)
Title |
---|
CHANDA J ET AL: "Heparin in calcification prevention of porcine pericardial bioprostheses" BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 18, no. 16, 1 August 1997 (1997-08-01), pages 1109-1113, XP004083119 ISSN: 0142-9612 * |
ZILLA P ET AL: "Carbodiimide Treatment Dramatically Potentiates the Anticalcific Effect of Alpha-Amino Oleic Acid on Glutaraldehyde-Fixed Aortic Wall Tissue" THE ANNALS OF THORACIC SURGERY, ELSEVIER, vol. 79, no. 3, 1 March 2005 (2005-03-01), pages 905-910, XP004761947 ISSN: 0003-4975 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021119391A1 (en) * | 2019-12-12 | 2021-06-17 | Edwards Lifesciences Corporation | Hybrid annuloplasty ring |
Also Published As
Publication number | Publication date |
---|---|
CN103705980A (en) | 2014-04-09 |
EP3453409A1 (en) | 2019-03-13 |
US20150238659A1 (en) | 2015-08-27 |
US9320830B2 (en) | 2016-04-26 |
WO2009085199A3 (en) | 2009-12-17 |
US10966822B2 (en) | 2021-04-06 |
CN101965205B (en) | 2014-01-01 |
EP2647393B1 (en) | 2018-10-17 |
US8748490B2 (en) | 2014-06-10 |
CN101965205A (en) | 2011-02-02 |
CA2710366C (en) | 2016-09-06 |
US20110165675A1 (en) | 2011-07-07 |
US20090164005A1 (en) | 2009-06-25 |
US20160235528A1 (en) | 2016-08-18 |
US9029418B2 (en) | 2015-05-12 |
US8357387B2 (en) | 2013-01-22 |
CN103705980B (en) | 2016-06-22 |
US10188511B2 (en) | 2019-01-29 |
EP2234657B1 (en) | 2015-08-19 |
EP3453409B1 (en) | 2022-04-27 |
US20190151083A1 (en) | 2019-05-23 |
CA2710366A1 (en) | 2009-07-09 |
EP2234657A2 (en) | 2010-10-06 |
US20140200659A1 (en) | 2014-07-17 |
US20130134064A1 (en) | 2013-05-30 |
EP2647393A1 (en) | 2013-10-09 |
US7972376B1 (en) | 2011-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10966822B2 (en) | Heart valve with reduced calcification | |
US20220241462A1 (en) | Bioprosthetic tissue having a reduced propensity for in vivo calcification | |
EP2640431B1 (en) | Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability | |
WO2000016820A1 (en) | Crosslinking of bioprosthetic material to mitigate post-implantation calcification |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880126930.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08866741 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2710366 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4754/DELNP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008866741 Country of ref document: EP |